(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 22 November 2001 (22.11.2001)

PCT

(10) International Publication Number WO 01/88114 A2

(51) International Patent Classification?: C12N 15/00

(21) International Application Number: PCT/EP01/05794

(22) International Filing Date: 18 May 2001 (18.05.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0012231.7

19 May 2000 (19.05.2000)

(71) Applicant (for all designated States except US): DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): PLAETINCK, Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). RENARD, Jean-Pierre [BE/BE]; Peter Benoitlaan 141, B-9050 Gentbrugge (BE). MORTIER, Katheriue [BE/BE]; Lange Boomgaardstraat 25, B- Gent (BE). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).
- (74) Agent: BOULT WADE TENNANT; Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR. CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR. HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

LR. LS. LT. LU, LV. MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO. CR. CU. CZ. DE. DK. DM. DZ. EE, ES. FI, GB, GD. GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO paient (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE EXPRESSION SYSTEM

(57) Abstract: There are provided DNA constructs, including replicable cloning vectors and expression vectors, comprising a bacteriophage promoter operably linked to an outron sequence. The expression vectors provided by the invention are useful in the expression of recombinant polypeptides in host cells or organisms and are particularly useful in expression of recombinant polypeptides in nematode worms such as C. elegans.

20

25

30

35

GENE EXPRESSION SYSTEM

Field of the invention

The invention relates to the expression of DNA, genes, cDNAs, proteins, peptides and parts thereof in the nematode worm *C. elegans*. In particular, the invention relates to methods of improving the translation of RNAs transcribed in *C. elegans* using a bacteriophage polymerase by introduction of a transsplice recognition site recognised by an SL1 transsplice recognition sequence into the DNA template transcribed by the bacteriophage polymerase.

15 Background to the invention

Eukaryotic versus prokaryotic expression.

Bacteriophage RNA polymerases, such as T7, T3, and SP6, and their corresponding promoters have been used extensively to drive the expression of heterologous genes in a variety of organisms. In copending International patent application No. WO 00/01846, Plaetinck et al. describe the use of the T7 system to express DNA, genes, cDNA, proteins and peptides of parts thereof and for the expression of double-stranded RNA (dsRNA) in the nematode model system C. elegans.

The bacteriophage expression systems are well known in the art for use in prokaryotic host cells, such as *E. coli*, and have the advantage that they provide simple and strong expression systems dependent only on one RNA polymerase and one well defined promoter. The application of such efficient expression systems in eukaryotic organisms is, however, not evident, mainly because messenger RNAs from eukaryotes and prokaryotes have a different

5

10

15

20

25

30

35

. - 2 -

structure, which has implications for translation efficiency and RNA stability.

Messenger RNAs of higher eukaryotes share a functionally essential 5' CAP structure. This structure is generated during a capping reaction that is linked exclusively to RNA polymerase II transcription. Prokaryotic RNA polymerases such as bacteriophage T3, T7 and SP6 polymerases do not provide messenger RNAs with such a CAP structure, leading to inefficient translation in eukaryotic systems (Fuerst et al. J. Mol. Biol:206:333-348 (1989)).

One way to improve translation of uncapped mRNAs in eukaryotic systems is by the insertion of an internal ribosome entry site (IRES) sequence 5' of the coding sequence. For example, Elroy-Stein, et al., Proc. Natl. Acad. Sci. USA 87:6743-6747 (1990), describe the cloning of the untranslated region of the ECMV virus downstream of the T7 promoter in order to enhance the efficiency of translation. In other systems translation of T7-derived transcripts may be enhanced by addition of a CAP structure derived from a capped transcript. For example, in Trypanosoma a 5' CAP structure is added to T7 generated RNA transcripts by a natural occurring trans-splicing reaction (Wirtz et al. NAR 22:3887-3894 (1994)).

Trans-splicing in C. elegans.

In *C. elegans* many mRNAs contain an identical short leader sequence, designated the spliced leader (SL). This splice leader is donated by a small RNA (SL RNA) via a trans-splicing reaction. This trans splicing was first observed by Krause *et al.*, Cell 49:753-61 (1987). The splice leader RNA exists as a small nuclear ribonucleoprotein particle and has the trimethylguanosine cap that is characteristic of

- 3 -

eukaryotic small nuclear RNAs. The trimethylguanosine cap present on the spliced leader RNA is transferred to the pre-mRNA during the trans-splicing reaction. Thereafter, the trimethylguanosine cap is maintained on the mature mRNA (Van Doren et al., Mol. Cell. Biol. 10:1769-1772 (1990). The trans-splicing signal for such a splice leader is essentially an intron missing only the 5' splice site, designated an 'outron'. An outron has essentially all the intron sequence including a trans-splice acceptor site homologous to a UUUCAG sequence preceded by a AU rich region (Conrad et al., NAR 21:913-919 (1993). Introduction of an outron into the 5' untranslated region of a C. elegans gene converts it to a trans-spliced gene (Conrad et al., EMBO J. 12:1249-1255 (1993); Conrad et al. Mol. Cell Biol. 11:1931-1926 (1991)) and introduction of donor sites in a natural trans-spliced C. elegans gene prevents trans-splicing and converts it into a more conventional gene.

20

25

30

35

5

10

15

Description of the invention.

Until recently, expression of heterologous and homologous genes in *C. elegans* was mainly achieved by linking an appropriate coding sequence to a selected *C. elegans* promoter. The present inventors have recently demonstrated that the recombinant gene expression in *C. elegans* can be based on the prokaryotic T7 expression system (WO 00/01846). However, the present inventors found that the expression system was far from being efficient, or at least the resulting expression was much lower than would be expected from this T7 related expression system. It was concluded that this low expression was mainly due to RNA instability or translation arrest. Furthermore, it was reasoned that fundamental differences between prokaryotic and eukaryotic

- 4 -

expression systems, particularly the requirement for capping of the 5' end of the mRNA for efficient translation in eukaryotic systems, was the main reason for this unexpectedly low expression.

5

10

15

20

25

30

35

The inventors have now developed a solution to the problem of the inefficiency of the T7 system in eukaryotic host cells and organisms, particularly in *C. elegans*, and have constructed a generally applicable expression system which allows for the efficient expression of genes, DNA, cDNA, peptides and proteins under the regulation of the T7 promoter in *C. elegans*.

Therefore, in accordance with a first aspect of the invention there is provided a DNA construct comprising a bacteriophage promoter operably linked to an outron sequence.

It is an essential feature of the DNA construct of the invention that the bacteriophage promoter and the outron sequence are "operably linked", that is to say they are arranged in a relationship permitting them to function in their intended manner. In this case, the bacteriophage promoter is positioned upstream of the outron sequence such that it is capable of promoting transcription of the outron sequence upon binding of an appropriate RNA polymerase, with the outron sequence forming the extreme 5' end of the resulting transcript.

The DNA construct may further comprise at least one restriction enzyme recognition site positioned downstream of and proximal to the outron sequence. Advantageously, the DNA construct may contain multiple restriction sites forming a multi-cloning site. The purpose of the restriction site/multi-cloning site is to facilitate cloning of a heterologous or homologous DNA fragment downstream of the outron sequence. A DNA construct comprising a bacteriophage promoter, an outron sequence and a restriction site/multi-cloning

site may therefore be referred to hereinafter as an 'outron cloning construct'.

5

10

15

20

25

30

35

in an outron cloning construct it is advantageous for the restriction site/multi-cloning site to be positioned fairly proximal to the outron sequence (e.g. within 100bp) such that a heterologous or homologous sequence inserted at this site may be cotranscribed with the outron sequence on a single mRNA. However, further sequence elements may be interposed between the outron sequence and the restriction site/multi-cloning site. For example, the general purpose vector pDW3123 described in the accompanying examples has a synthetic intron A sequence between the outron sequence and the multi-cloning site.

In one preferred embodiment of the invention, the DNA construct is a replicable cloning vector, such as, for example, a plasmid vector. In addition to the bacteriophage promoter, outron sequence and optional restriction site/multi-cloning site, the vector may further contain one or more of the general features commonly found in cloning vectors, for example an origin of replication to allow autonomous replication within a host cell and a selective marker, such as an antibiotic resistance gene. Although not essential, the vector may also contain a poly-adenylation signal to stabilize and process the 3' end of the mRNA transcribed from the bacteriophage promoter. A preferred example is the 3'UTR from the C. elegans unc-54 gene, but any other 3'UTR or polyadenylation signal may be used.

Outron-containing DNA constructs according to the invention may be easily be constructed from the component sequence elements using standard recombinant techniques well known in the art and described, for example, in F. M. Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994).

- 6 -

Outron sequences for use in the constructs of the invention may be isolated from natural *C. elegans* genes using standard molecular biology techniques. For example, a natural outron sequence might be amplified using the polymerase chain reaction or an equivalent amplification technique using *C. elegans* genomic DNA as a template. Alternatively, synthetic outron sequences may be synthesised, for example, by annealing two complementary single stranded oligonucleotides, as illustrated in the accompanying examples. Once a DNA fragment comprising the outron sequence has been obtained in would be a matter of routine to assemble an outron construct by linking the outron in the correct orientation relative to the bacteriophage promoter.

5

10

15

20

25

30

35

The sequences of the commonly used bacteriophage promoters, e.g. T7, T3 and SP6, are well known in the art and oligonucleotides containing functional phage promoter sequences can be readily synthesised using standard oligonucleotide synthesis techniques. It would be a matter of routine to insert such a synthetic promoter sequence into, for example, a plasmid vector backbone containing, for example, an origin of replication a selective marker and a suitable restriction site. Alternatively, one of the many plasmid vectors containing bacteriophage promoter sequences known in the art may be used as the starting point for the construction of a plasmid-based outron cloning vector. The known vectors generally contain, in addition to the phage promoter sequence, one or more restriction sites conveniently positioned downstream of the phage promoter and also a bacterial origin of replication and a selective marker. Once the vector backbone is in place the outron sequence may simply be inserted in the appropriate position downstream of the bacteriophage promoter.

In a particularly useful embodiment the invention

5

10

15

20

25

30

35

provides a DNA construct for use in bacteriophage promoter-driven expression of a polypeptide in a eukaryotic host cell or organism. This construct comprises a bacteriophage promoter operably linked to a DNA sequence such that it is capable of initiating transcription of the DNA sequence upon binding of an appropriate RNA polymerase to the promoter, wherein the aforesaid DNA sequence comprises an outron sequence and at least one open reading frame positioned downstream of the outron sequence.

The open reading frame may be essentially any protein-encoding DNA sequence bounded by start and stop codons. This protein-encoding DNA sequence may include introns, as both trans-splicing and cissplicing can occur together.

A DNA construct according to this embodiment of the invention, which may be referred to hereinafter as an 'outron expression construct', may be derived from an outron cloning construct by insertion of a heterologous or homologous protein-encoding DNA fragment into the restriction site/multi-cloning site. It is essential that the heterologous or homologous DNA fragment be inserted downstream of the outron sequence such that the two sequences may be cotranscribed, with the outron sequence forming part of the 5' untranslated region of the resulting mRNA.

The outron expression construct may advantageously form an expression vector, such as, for example, a plasmid vector. Most preferably, the expression vector will be one suitable for use in the nematode worm C. elegans. In addition to the bacteriophage promoter, outron sequence and protein-encoding DNA sequence (open reading frame), the expression vector may further contain one or more of the general features commonly found in expression vectors, for example an origin of replication to allow autonomous replication within a bacterial host cell

- 8 -

and a selective marker, such as an antibiotic resistance gene. The vector may also contain a poly-adenylation signal to stabilize and process the 3' end of the mRNA transcribed from the bacteriophage promoter. A preferred example is the 3'UTR from the C. elegans unc-54 gene, but any other 3'UTR or polyadenylation signal may be used. An additional element, such as for example a synthetic intron, may be interposed between the outron sequence and the open reading frame.

5

10

15

20

25

30

35

It is important that the open reading frame is positioned downstream of and proximal to the outron sequence in the expression construct such that (i) the two elements are co-transcribed to form a single mRNA and (ii) the outron sequence forms part of the 5' untranslated region of the mRNA. If the appropriate splicing machinery and a supply of SL RNAs is provided by the eukaryotic host cell or organism then the uncapped 5' end of the pre-mRNA transcribed from the expression construct will be replaced with a capped splice leader via the trans-splicing reaction. This will greatly increase the efficiency of translation in a eukaryotic host system.

The use of an outron sequence at the extreme 5' end of the RNA provides a solution to the problem of reduced expression efficiency in eukaryotic systems wherever the type of promoter/polymerase used to drive gene expression leads to the production of uncapped transcripts, provided that the host cell or organism produces the spliced leader RNAs required for the trans-splicing reaction.

Outron sequences which may be utilised in accordance with the invention include naturally occurring outron sequences isolated from SL1-specific C. elegans genes (Conrad, R. Functional analysis of a C. elegans trans-splice acceptor. Nucleic Acids Res. 1993, 21(4), pp913-919; Conrad, R. SL1 trans-splicing

- 9 -

specified by AU-rich synthetic RNA inserted at the 5' end of Caenorhabditis elegans pre-mRNA. RNA. 1995, 1(2), pp164-170) and also synthetic outron sequences which are functionally equivalent to the natural C. elegans outron sequences, including variants of naturally occurring C. elegans outrons. The phrase "functionally equivalent" means that the synthetic intron is recognised by the C. elegans trans-splicing machinery and can be trans-spliced to a C. elegans splice leader RNA, preferably the SL1 splice leader.

5

10

15

20

25

30

35

Experimental evidence indicates that transsplicing in *C. elegans* is signalled by an AU-rich
intron-like sequence followed by a splice acceptor
site (Conrad et al 1993 and 1995). For the purposes
of the present application the terms "outron" or
"outron sequence" should be interpreted as referring
to both the AU-rich region from the 5' end of the premRNA to the trans-splice acceptor site and the transsplice acceptor site itself. In connection with the
DNA constructs of the invention, the terms "outron"
and "outron sequence" refer to features present in the
DNA which encodes the pre-mRNA.

The consensus splice acceptor site for transsplicing of outrons and the consensus 3' splice acceptor site for cis-splicing of introns are essentially identical (UUUCAG). Moreover, a normally trans-spliced acceptor site can be efficiently cisspliced when a donor splice site is inserted upstream within the outron sequence. It is therefore important that the outron constructs described herein do not contain any potential splice donor sequence upstream of the splice acceptor within the outron and downstream of the transcription start site such that it will be transcribed in the mRNA encoded by the construct. If such a site were present than there would be a potential for cis-splicing rather than

trans-splicing.

5

10

15

20

25

30

35

It has also been observed that the overall length of the outron has an effect on the efficiency of trans-splicing, longer outrons in general working better than shorter ones (Conrad et al. 1995).

Advantageously, the outron sequences for inclusion into the outron constructs described herein should be greater than about 50nt in length.

A synthetic outron containing an AT stretch and a TTTTCAG sequence has been shown to be functional in *C. elegans*. As illustrated in the accompanying Examples, the insertion of an outron sequence into the 5' untranslated region of GFP reporter construct, downstream of the promoter and upstream of the GFP open reading frame, is required for optimal expression of bacteriophage RNA polymerase transcribed reporter gene mRNA in *C. elegans*.

Suitable bacteriophage promoters which may be used in the DNA constructs according to the invention include T7, T3 and SP6 promoters, with T7 being the most preferred. As discussed above, these bacteriophage promoters have long been known to be useful tools in molecular biology since they can provide simple and strong expression systems dependent only on the binding of the specific or cognate RNA polymerase.

In a still further aspect, the invention provides a method for expressing a recombinant polypeptide in *C. elegans*, which method comprises:

introducing an outron expression construct, as described above, said construct being an expression vector suitable for use in *C. elegans*, into a *C. elegans* strain which expresses an RNA polymerase specific for the bacteriophage promoter present in said DNA construct in one or more tissues or cell

- 11 -

types.

5

10

15

20

25

An outron expression vector for use in this method may be constructed by inserting DNA encoding the polypeptide of interest into an outron cloning vector, as described above. The vector must be one which is suitable for use in *C. elegans*, plasmid-based vectors are the most preferred.

The C. elegans worms are preferably transgenic worms carrying a transgene capable of expressing the RNA polymerase in one or more tissues or cell types. The term "transgene capable of expressing" as used herein means a nucleic acid molecule comprising a nucleotide sequence encoding the polymerase operably linked to a promoter. The promoter may be any promoter which functions in C. elegans and may be general (i.e. active in substantially all tissues and cell types), tissue-specific, cell type-specific, constitutive, inducible etc. Most preferably, the promoter will exhibit tissue or cell type-specificity. With the use of a tissue or cell type-specific promoter of the appropriate specificity it is possible to control the site of RNA polymerase expression within C. elegans and hence control the site of expression of the recombinant polypeptide.

Methods for the construction of transgenic *C*. elegans worms are known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

30

35

In a further aspect the invention provides a kit for use in recombinant expression of a polypeptide in *C. elegans*, the kit comprising an outron cloning construct, as described above, and optionally a supply of *C. elegans* nematode worms expressing an RNA polymerase specific for the bacteriophage promoter

- 12 -

present in the said outron cloning construct in one or more tissues or cell types.

The kit might further contain control inserts and control constructs, e.g. a reporter gene inserts and constructs which could be used to check efficiency of cloning steps and transfection steps, respectively. It might also contain constructs which may be used as selectable markers in the transfection procedure, e.g. a rol 6 plasmid (see below).

5

10

15

20

25

30

35

The invention further provides methods for the construction of transgenic C. elegans expressing a recombinant polypeptide in one or more tissues or cell types. One such method comprises introducing an outron expression construct, as described above, said construct being an expression vector suitable for use in C. elegans comprising an open reading frame encoding the desired recombinant polypeptide, into a C. elegans strain which expresses an RNA polymerase specific for the bacteriophage promoter present in said DNA construct in one or more tissues or cell types, and isolating transgenic C. elegans lines which stably express the said polypeptide. The C. elegans strain expressing the polymerase is preferably a transgenic strain carrying a transgene capable of expressing the RNA polymerase in one or more tissues or cell types, as described above. As aforesaid, transgenic C. elegans lines can readily be constructed using standard techniques well known in the art.

In an alternative approach, the method may comprise introducing into a background *C. elegans* strain (i) an outron expression construct, as described above, said construct being an expression vector suitable for use in *C. elegans* comprising an open frame encoding the desired recombinant polypeptide, and (ii) a DNA construct suitable for expression of an RNA polymerase specific for the

- 13 -

bacteriophage promoter present in the outron expression construct in one or more tissues or cell types of *C. elegans*, and isolating transgenic *C. elegans* lines which stably express the said polypeptide. The second DNA construct may, advantageously, be an expression vector comprising a nucleotide sequence encoding the polymerase operably linked to a promoter having the appropriate tissue or cell type specificity.

5

10

15

20

25

30

35

In carrying out the methods of the invention one may employ standard techniques well known in the art for construction and selection of transgenic C. elegans lines. Such techniques are described, for example, in techniques described in Methods in Cell Biology, vol 84; Caenorhabditis elegans: modern biological analysis of an organism, ed. Epstein and Shakes, academic press, 1995. Foreign DNA (e.g. plasmid DNA) may be introduced into C. elegans using microinjection or ballistic transformation, as described in the applicant's co-pending International patent application No. WO 99/49066. In order to facilitate the selection of transgenic strains a marker plasmid may be co-introduced with the transgenes. A typical example is the plasmid pRF4 (Mello, C. C. et al. EMBO J. 10, 3959-3970 (1991)) which carries the rol-6 gene. C. elegans expressing rol-6 can be identified by screening for the roller phenotype. Any other C. elegans dominant selectable phenotypic marker, of which there are many known in the art, may be used to facilitate selection of transgenic lines. A useful example is green fluorescent protein (or any of the equivalent autonomous fluorescent proteins known in the art).

In a still further aspect the invention provides transgenic *C. elegans* worms which contain an outron expression construct, as described above, said

- 14 -

construct being an expression vector suitable for use in *C. elegans*, and which further express an RNA polymerase specific for the bacteriophage promoter present in the outron expression construct in one or more tissues or cell types.

The present invention will be further understood with reference to the following non-limiting Examples, together with the accompanying drawings in which:

10

15

5

Figure 1 illustrates the construction of a T7-outron-GFP vector. (A) sequence of the synthetic outron produced by annealing oligonucleotides o-GN59 and o-GN60. (B) summary of the strategy used to construct vector pDW3124.

Figure 2 shows plasmid maps for pDW3123 (outron cloning vector) and pDW3124 (outron expression vector for GFP expression).

20

30

Figure 3 is a plasmid map of pGN148 which contains a T7 RNA polymerase coding sequence under the regulation of the *C. elegans* SERCA promoter.

Figure 4 illustrates the nucleotide sequence of pGN148.

Figure 5 illustrates the nucleotide sequence of pDW 3123 annotated to show the positions of the T7 promoter, outron, synthetic intron A, multi-cloning site and unc-54 3' UTR sequences and also the ampicillin resistance gene.

Figure 6 illustrates the nucleotide sequence of pDW 3124 annotated to show the positions of the T7 promoter, outron, synthetic intron A, GFP with introns and unc-54 3' UTR sequences and also the ampicillin

, !

- 15 -

resistance gene.

5

10

15

20

Example 1 -Construction of a T7-outron-GFP containing vector (pDW3124)

A SL1 trans-splice acceptor site (outron) was cloned into a vector downstream of the T7 promoter and upstream of the GFP to be expressed.

A synthetic outron consisting of two partially overlapping oligonucleotides (o-GN59 and o-GN60, see Figure 1) was inserted into a XbaI/XmaI digested T7 promoter GFP construct. Briefly, 25µl o-GN59 and 25µl o-GN60 (100µM) were denatured for 5 minutes at 94°C, annealed for 30 minutes at 68°C then cooled to 4°C. lpl of XmaI/XbaI digested pDW3120 and 10pl of the annealed oligos were then ligated using T4 ligase overnight at 16°C, transformed into competent E. coli and analysed by restriction digestion and DNA sequencing, all according to standard molecular biology procedures. The resulting vector was designated pDW3124 (Figures 1 and 2).

The outron contains an AU rich sequence followed by a splice-acceptor site as described by Conrad et al, NAR 21:913-919 (1993) (see Figure 1).

Example 2-Construction of a T7-Outron MCS vector 25

> A general purpose vector was constructed to facilitate expression of other DNA sequences in C. elegans under the control of the T7 promoter. This was done by digesting vector pDW3124 with HindII (position 179) and PvuII (position 1029) (partial digest) and re-ligating the blunt ends, resulting in vector pDW3123 (Figure 2).

30

35

- 16 -

Example 3-The expression of heterologous genes in C. elegans regulated by the T7 promoter requires trans-splicing.

Wild-type *C. elegans* nematodes where co-injected with various combinations of the following test plasmids:

1) GFP reporter plasmid
GFP: pDW2020

10 outron-GFP: pDW2024
T7 promoter-GFP: pDW3120
T7 promoter-outron-GFP: pDW3124

2) T7 polymerase expression plasmid SERCA T7 polymerase: pGN148 together with pRF-4 (rol-6) as marker.

For every co-injection experiment, a total concentration of 200 ng DNA/ μ l was used (plasmid concentration was 50 ng/ μ l and carrier DNA was added up to 200ng/ μ l). For every co-injection ±15 adult worms were injected.

F1 offspring showing the marker rol-6 phenotype were isolated and then selected for further study. The next generation (F2) of the roller lines were screened for GFP expression in the pharynx, vulva, tail and body wall muscles. These are the tissues in which the bacteriophage T7 RNA polymerase is known to be expressed when under the control of the *C. elegans* SERCA promoter (as in the construct pGN148)

The results are shown in Table 1 below, which indicates the number of lines expressing GFP vs total number of lines isolated.

35

20

25

30

15

20

		1	2	3	
	A	Construct	no T7- polymerase construct	with T7-polymerase construct (50ng) pGN148	
	В	GFP (50ng) pDW2020	0/8	2/6*	
	С	outron::GFP (50ng) pDW2024	0/11	3/8*	
5	D	T7-promoter::GFP (50ng) pDW3120	0/3	0/5	,
	E	T7-promoter::outron::GFP (50ng) pDW3124	0/7	13/13	

* GFP-expression most probably result of recombination 10 in the extrachromosomal array

No GFP expression was observed in the experiments where the T7 RNA polymerase was absent (cells B2, C2, D2, E2).

In the experiments where the T7 RNA polymerase expressing vector was co-injected with GFP vectors without a T7 promoter, as in the cells B3 and C3, GFP expression was sometimes observed. This is probably due to recombination events in the extrachromosomal arrays, resulting in transcription of GFP directly from the SERCA promoter.

In the experiments where the T7 promoter-GFP construct
and the SERCA T7 RNA polymerase where co-injected, no
GFP expression could be observed (cell D3). In
contrast, all of the lines isolated from the
experiments where the GFP transcript contained an
outron at its 5' site (n=13) expressed GFP (cell E3).

The outron is a favourable target for SL1
trans-splicing. Since SL1 RNA molecules contain a 5'

- 18 -

trimethylguanosine CAP structure which is transferred to the mature mRNA this results in improved translation of the RNA and hence better expression of GFP. Without the outron the T7 RNA polymerase transcripts do not carry a CAP structure at their 5' end, leading to inefficient translation. The results of this experiment illustrate the importance of trans-splicing for efficient expression of heterologous and homologous genes transcribed by prokaryotic polymerases in *C. elegans*.

SEQUENCE LISTING

5

10

15

SEQ ID NO: 1 Oligonucleotide o-GN59 SEQ ID NO: 2 Oligonucleotide 0-GN60 SEQ ID NO: 3 Plasmid pDW3123

SEQ ID NO: 4 Plasmid pDW3124 SEQ ID NO: 5 Plasmid pGN148

11

WQ 01/88114

- 19 -

PCT/EP01/05794

Claims:

1. A DNA construct comprising a bacteriophage promoter operably linked to an outron sequence.

5

2. A DNA construct as claimed in claim 1 which further comprises at least one restriction enzyme recognition site positioned downstream of and proximal to the outron sequence.

10

- 3. A DNA construct as claimed in claim 2 which comprises a multi-cloning site positioned downstream of and proximal to the outron sequence.
- 4. A DNA construct as claimed in claim 2 or claim 3 which further comprises a DNA fragment inserted at the said restriction site or at a restriction site within the said multi-cloning site.
- 20 5. A DNA construct as claimed in any one of claims 1 to 4 which is a replicable cloning vector.
 - 6. A DNA construct as claimed in any one of claims 1 to 5 wherein the outron sequence comprises a 3' splice acceptor site having the sequence TTTCAG preceded by an AT-rich region.
 - 7. A DNA construct as claimed in claim 6 wherein the outron sequence comprises the nucleotide sequence illustrated in Figure 1A.
 - 8. A DNA construct as claimed in any one of claims 1 to 7 wherein the bacteriophage promoter is the T7, T3 or SP6 promoter.

35

į

25

30

9. A DNA construct for use in bacteriophage promoter-driven expression of a polypeptide in a

5

15

20

25

30

eukaryotic host cell or organism, which construct comprises a bacteriophage promoter operably linked to a DNA sequence such that it is capable of initiating transcription of said DNA sequence upon binding of the appropriate RNA polymerase to the promoter, wherein the said DNA sequence comprises an outron sequence and at least one open reading frame positioned downstream of the outron sequence.

- 10 10. A DNA construct as claimed in claim 9 which is an expression vector.
 - 11. A DNA construct as claimed in claim 9 or claim 10 wherein the outron sequence comprises a 3' splice acceptor site having the sequence TTTCAG preceded by an AT-rich region.
 - 12. A DNA construct as claimed in claim 11 wherein the outron sequence comprises the nucleotide sequence illustrated in Figure 1A.
 - 13. A DNA construct as claimed in any one of claims 9 to 12 wherein the bacteriophage promoter is the T7, T3 or SP6 promoter.
 - 14. A kit for use in recombinant expression of a polypeptide in *C. elegans*, the kit comprising a DNA construct as claimed in any one of claims 1 to 3, and optionally *C. elegans* worms expressing an RNA polymerase specific for the bacteriophage promoter present in said DNA construct in one or more tissues or cell types.
- 15. A method for expressing a recombinant polypeptide in *C. elegans* which method comprises: introducing a DNA construct as claimed in any one

- 21 -

of claims 9 to 13, said construct being an expression vector suitable for use in *C. elegans*, into a *C. elegans* strain which expresses an RNA polymerase specific for the bacteriophage promoter present in said DNA construct in one or more tissues or cell types.

5

10

15

;20

; .

25

30

35

16. A method of generating transgenic *C. elegans* expressing a recombinant polypeptide, which method comprises:

introducing a DNA construct as claimed in any one of claims 9 to 13 comprising an open reading frame encoding the recombinant polypeptide, said construct being an expression vector suitable for use in C. elegans, into a C. elegans strain which expresses an RNA polymerase specific for the bacteriophage promoter present in said DNA construct in one or more tissues or cell types, and

isolating transgenic *C. elegans* lines which stably express the said polypeptide.

17. A method of generating transgenic *C. elegans* expressing a recombinant polypeptide, which method comprises:

introducing into *C. elegans* (i) a first DNA construct as claimed in any one of claims 9 to 13 comprising an open reading frame encoding the recombinant polypeptide, said construct being an expression vector suitable for use in *C. elegans*, and (ii) a second DNA construct suitable for expression of an RNA polymerase specific for the bacteriophage promoter present in the first DNA construct in one or more tissues or cell types of *C. elegans*, and

isolating transgenic *C. elegans* lines which stably express the said polypeptide

- 22 -

18. Transgenic C. elegans which contain a DNA construct as claimed in any one of claims 9 to 13, said construct being an expression vector suitable for use in C. elegans, and which further express an RNA polymerase specific for the bacteriophage promoter present in said DNA construct in one or more tissues or cell types.

5


FIG. 1(A).

Xbal overhang Sspl 3'splice acceptor


CTAGATTACAACTAATTATACTTATTTGAATATTCAAATTTTCAGAC 0-GN59


TAATGTTGATTAATATGAATAAACTTATAAGTTTAAAAGTCTGGGCC 0-GN60

Xmal overhang










F16.3.



F1G. 4.

Nucleotide sequence of pGN148

atgactgctccaaagaagaagcgtaaggtaccggtaatgaacacgattaacatcgctaagaacgacttctc tgacatcgaactggctgctatcccgttcaacactctggctgaccattacggtgagcgtttagctcggtaag tttaaacatctagatactaactaacgattaacatttaaattttcagcgaacagttggcccttgagcatgag $\verb|tcttacgagatgggtgaagcacgcttccgcaagatgtttgagcgtcaacttaaagctggtgaggttgcggaagcttcaacttaaagctggtgaggttgcggaagcttgcggaagcttccgcaagatgtttgagcgtcaacttaaagctggtgaggttgcggaagcttccgcaagatgtttgagcgtcaacttaaagctggtgaggttgcggaagcttccgcaagatgtttgagcgtcaacttaaagctggtgaggttgcggaagctgcgcgaagatgtttgagcgtcaacttaaagctggtgaggttgcggaaggttgcggaagctgaggttgaggttgcggaagctgaggttgagggttga$ taacgctgccgccaagcctctcatcactacccctactccctaagatgattgcacgcatcaacgactggtttg ${\tt aggaagtgaaagctaagcgcggcaagcgcccgacagccttccagttcctgcaagaaatcaagccggaagcc}$ gtagcgtacatcaccattaagaccactctggcttgcctaaccagtgctgacaatacaaccgttcaggctgt agcaagcgcaatcggtcgggccattgaggacgaggctcgcttcggtcgtatccgtgaccttgaagctaagc acttcaagaaaacgttgaggaacaactcaacaagcgcgtagggcacgtctacaagaaagcatttatgcaa gttgtcgaggctgacatgctctctaagggtctactcggtggcgaggcgtggtcttcgtggcataaggaaga ctctattcatgtaggagtacgctgcatcgagatgctcattgagtcaaccggagtggttagcttacaccgcc aaaatgetggegtagtaggteaagaetetgagaetategaaetegeaeetgaataegetgaggetategea acccgtgcaggtgcgctggctggcatctctccgatgttccaaccttgcgtagttcctcctaagccgtggac tggcattactggtggtggctattgggctaacggtcgtcgtcctctggcgctggtgcgtactcacagtaaga aagcactgatgcgctacgaagacgtttacatgcctgaggtgtacaaagcgattaacattgcgcaaaacacc gcatggaaaatcaacaagaaagtcctagcggtcgccaacgtaatcaccaagtggaagcattgtccggtcga ggacatccctgcgattgagcgtgaagaactcccgatgaaaccggaagacatcgacatgaatcctgaggctc teacegegtggaaaegtgetgeegetgetgtgtaeegeaaggaeaaggetegeaagtetegeegtateage cttgagttcatgcttgagcaagccaataagtttgctaaccataaggccatctggttcccttacaacatgga ctggcgcggtcgtgtttacgctgtgtcaatgttcaacccgcaagctaacgatatgaccaaaggactgctta cgctggcgaaaggtaaaccaatcggtaaggaaggttactactggctgaaaatccacggtgcaaactgtgcg $\verb|ggtgtcgataaggttccgttccctgagcgcatcaagttcattgaggaaaaccacgagaacatcatggcttg|$ cgctaagtctccactggagaacacttggtgggctgagcaagattctccgttctgcttccttgcgttctgct ttgagtacgctggggtacagcaccacggcctgagctataactgctcccttccgctggcgtttgacgggtct ctctatcctactaactaacgaagcttatttaaattttcagaacttgcttcctagtgaaaccgttcaggaca gtagttaccgtgaccgatgagaacactggtgaaatctctgagaaagtcaagctgggcactaaggcactggc tggtcaatggctggcttacggtgttactcgcagtgtgactaagcgttcagtcatgacgctggcttacgggt ctgatgttcactcagccgaatcaggctgctggatacatggctaagctgatttggggaatctgtgagcgtgac ataagaagactggagagattettegeaagegttgegetgtgeattgggteaeteeggatggttteeetgtg tggcaggaatacaagaagcctattcaaacgcgtttgaacctgatgttcctcggtcagttccgcttacagcc $\verb|taccattaacaccaacaagatagcgagattgatgcacacaaacaggagtctggtatcgctcctaactttg|$ tacacagccaagacggtagccaccttcgtaagactgtagtggggcacacgagaagtacggaatcgaatct tttgcactgattcacgactccttcggtaccattccggctgacgctgcgaacctgttcaaagcagtgcgcga aactatggttgacacatatgagtcttgtgatgtactggctgatttctacgaccagttcgctgaccagttgc acgagtctcaattggacaaaatgccagcacttccggctaaaggtaacttgaacctccgtgacatcttagag tcggacttcgcgttcgcgtaagaattccaactgagcgccggtcgctaccattaccaacttgtctcggtgtca ttttcagcatctcgcgcccgtgcctctgacttctaagtccaattactcttcaacatccctacatgctcttt ctccctgtgctcccaccccctatttttgttattatcaaaaaacttcttcttaatttctttgtttttagc aaaaaaattgtgctccctcccccattaataataattctatcccaaaatctacaCaatgttctgtgtacac $\verb|ttcttatgtttttttacttctgataaattttttttgaaacatcatagaaaaaaccgcacacaaaatacct|\\$ tatcatatgttacgtttcagtttatgaccgcaatttttatttcttcgcacgtctgggcctctcatgacgtc atacattcccaatataccaaacataactgtttcctactagtcggccgtacggggccctttcgtctcgcgcgt ttcggtgatgacggtgaaaacctctgacacatgcagctcccggagacggtcacagcttgtctgtazgcgga cggcatcagagcagattgtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgtaaggaga

FIG. 4 (CONTINUED 1.)

aaataccgcatcaggcggccttaagggcctcgtgatacgcctatttttataggttaatgtcatgataataa tggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaa atacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaa gagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttg ctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaa ctggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttt taaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccatac actatteteagaatgaettggttgagtaeteaeeagteaeagaaaageatettaeggatggeatgaeagta aggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaac cggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttg gtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatc tacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgat taagcattggtaactgtcagaccaagtttacteatatatactttagattgatttaaaacttcattttaat ttaaaaggatetaggtgaagateetttttgataateteatgaeeaaaateeettaaegtgagttttegtte $\verb|cactgagegtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctg|$ ctgcttgcaaacaaaaaaccaccgctaccageggtggtttgtttgeeggatcaagagctaccaactcttt ttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggc cagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgg gctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacag cgtgagcattgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggt cggaacaggagagcgcacgaggggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttc aacgcggcctttttacggttcctggccttttgctggcctttttgctcacatgttcttcctgcgttatcccc tgattetgtggataacegtattaccgcetttgagtgagetgataccgctcgccgcagccgaacgaccgagc g cage gag teag t gag e gag gaa geg gaa gag e gec caa tae geaa a a ceg cet ct cccc geg e g t t g g ceg a gag e gattcatta atg cag ctg g cac g ac ag g t t t c ccg a ctg g a a g cg g g cag c g c a a c g c a a t t a a t g t a g c g c a g c g c a c g c a a c g c a a t t a a t g t a g c g c a c g c a c g c a c g $\tt gagttagctcactcattaggcaccccaggctttacactttatgcttccggctcgtatgttgtgtagaattg$ tgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagctgtaagtttaaacatga tacgctaacaacttggaaatgaaataagcttgcatgcctgcagagcaaaaaaatactgcttttccttgcaa aattoggtgctttcttcaaagagaaacttttgaagtoggcgcgagcatttcctttttgacttctcttt ccaaatgtgtgctcattttggagccccgtgtggggcagctgctctcaatatattactagggagacgaggag ggggaccttatcgaacgtcgcatgagccattcttcttcttctttatgcactctcttcaccacacattagaagaggctgacgatgttaggaaaaagagaacggagccgaaaaaacatccgtagtaagtcttccttttaag ccgacactttttagacagcattcgccgctagttttgaagtttaaattttaaaaaataaaaattagtttcaa ttttttttaattactaaataggcaaaagttttttcaagaactctagaaaaactagcttaattcatgggtac tagaaaaattcttgttttaaatttaatatttatcttaagatgtaattacgagaagcttttttgaaaattct ${\tt caattaaaagaatttgccgatttagaataaaagtcttcagaaatgagtaaaagctcaaattagaagtttgt}$ ttttaaaggaaaaacacgaaaaaagaacactatttatcttttcctccccgcgtaaaattagttgttgtgat a a tagtgat ccgctgtctatttgcactcggctcttcacaccgtgcttcctctcacttgacccaacaggaaaaaaaaacatcacgtctgagacggtgaattgccttatcaagagcgtcgtctctttcacccagtaacaaaaa ctccacacctccgcctccagcagcacacaatcatcttcgtgtgttctccgacgattccttgtatgccgc ggtegtgaatgcaccacattcgacgcgcaactacacaccaccacttttcggtggtattactacacgtca tegttgttegtagteteecegetetttegteeceacteacteeteattatteecettggtgtattgatttt tttaaatggtacaccactcctgacgtttctaccttcttgttttccgtccatttagattttatctggaaatt tctcatcaaaaaaaagttgataaagaaaactggttattcagaaagagtgtgtctcgttgaaattgattca aaaaaaaattcccaccctcgcttgtttctcaaaatatgagatcaacggattttttccttctcgattcaat tttttgctgcgctctgtctgccaaagtgtgtgtgtgtccgagcaaaagatgagagaatttacaaaacagaaatg

FIG. 4 (CONTINUED 2.)

 ${\tt aaaaaaaagttggccaaataatgaagttttatccgagattgatgggaaagatattaatgttctttacggttt}$ ggaggggagagagagatagattttcgcatcaaactccgccttttacatgtcttttagaatctaaaatagat ttttctcatcatttttaatagaaaatcgagaaattacagtaatttcgcaattttcttgccaaaaatacacg aaatttgtgggtctcgccacgatctcggtcttagtggttcatttggtttaaaagtttataaaatttcaaat $\verb|tctagtgtttaatttccgcataattggacctaaaattgggtttttgtcatcattttcaacaagaaatcgtga|\\$ aaatcctgttgtttcgcaattttcttttcaaaaatacacgaaatatatggtaattttcccgaaatattgagg gtctcgccacgatttcagtcacagtggccaggatttatcacgaaaaagttcgcctagtctcacatttccg gaaaaccgaatctaaattagttttttgtcatcattttgaacaaaaatcgagacatccctatagtttcgca $\verb|attttcgtcgcttttctctccaaaaatgacagtctagaattaaaattcgctggaactgggaccatgatatc|$ ttttctccccgtttttcattttatttttattacactggattgactaaaggtcaccaccaccgccagtgtg tgccatatcacacacacacacacacacatgtcgagattttatgtgttatccctgcttgatttcgttccgt tgtctctctctctattcatcttttgagccgagaagctccagagaatggagcacacaggatcccggcgcg $\tt cgatgtcgtcggagatggcgccgcctgggaagccgccgagagatatcagggaagatcgtctgatttctcc$ $\verb|tcggatgccacctcatctccgagtttctccgcctgttactccctgccgaacctgatatttcccgttgtcg|$ tcattcattattccttttcatcatca a a ctag catttcttactttatttatttttcaattttcaattttcagataaaaccaaactacttgggttacagccgtcaacagatccccgggattggccaaaggacccaaag cagaaaaa

F1G.5.

. .

T7 promoter ------1 AGCTTGGCGC CTAATACGAC TCACTATAGG GCTGCAGGTC GACTCTAGAT TACAACTAAT TATACTTATT TCGAACCGCG GATTATGCTG AGTGATATCC CGACGTCCAG CTGAGATCTA ATGTTGATTA ATATGAATAA synth, intron A 71 TGAATATTCA AATTTCAGA CCCGGGATTG GCCAAAGGAC CCAAAGGTAT GTTTCGAATG ATACTAACAT ACTIATAAGI TIAAAAGICI GGGCCCTAAC CGGITTCCIG GGITTCCATA CAAAGCITAC TAIGATIGIA MCS synth. intron A ------141 AACATAGAAC ATTTTCAGGA GGACCCTTGG CTAGCGTCCT GCTGGGATTA CACATGGCAT GGATGAACTA
TTGTATCTTG TAAAAGTCCT CCTGGGAACC GATCGCAGGA CGACCCTAAT GTGTACCGTA CCTACTTGAT -----211 TACAAATAGG GCCGGCCGAG CTCCGCATCG GCCGCTGTCA TCAGATCGCC ATCTCGCGCC CGTGCCTCTG
ATGTTTATCC CGGCCGGCTC GAGGCGTAGC CGGCGACAGT AGTCTAGCGG TAGAGCGCGG GCACGGAGAC 281 ACTICTAAGT CCAATTACTC TTCAACATCC CTACATGCTC TTCTCCCTG TGCTCCCACC CCCTATTTTT TGAAGATTCA GGTTAATGAG AAGTTGTAGG GATGTACGAG AAAGAGGGAC ACGAGGGTGG GGGATAAAAA unc-54 3' UTR 351 GTTATTATCA AAAAAACTTC TTCTTAATTT CTTTGTTTTT TAGCTTCTTT TAAGTCACCT CTAACAATGA CAATAATAGT TTTTTTGAAG AAGAATTAAA GAAACAAAAA ATCGAAGAAA ATTCAGTGGA GATTGTTACT 421 AATTGTGTAG ATTCAAAAAT AGAATTAATT CGTAATAAAA AGTCGAAAAA AATTGTGCTC CCTCCCCCA
TTAACACATC TAAGTTTTTA TCTTAATTAA GCATTATTTT TCAGCTTTTT TTAACACGAG GGAGGGGGGT 491 TTAATAATAA TTCTATCCCA AAATCTACAC AATGTTCTGT GTACACTTCT TATGTTTTT TTACTTCTGA
AATTATTATT AAGATAGGGT TTTAGATGTG TTACAAGACA CATGTGAAGA ATACAAAAAA AATGAAGACT 561 TAAATTTTTT TTGAAACATC ATAGAAAAAA CCGCACACAA AATACCTTAT CATATGTTAC GTTTCAGTTT ATTTAAAAA AACTTTGTAG TATCTTTTTT GGCGTGTGTT TTATGGAATA GTATACAATG CAAAGTCAAA 631 ATGACCGCAA TTTTTATTTC TTCGCACGTC TGGGCCTCTC ATGACGTCAA ATCATGCTCA TCGTGAAAAA TACTGGCGTT AAAAATAAAG AAGCGTGCAG ACCCGGAGAG TACTGCAGTT TAGTACGAGT AGCACTTTTT unc-54 3' UTR 701 GTTTTGGAGT ATTTTTGGAA TTTTTCAATC AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTTGCTTT CAAAACCTCA TAAAAACCTT AAAAAGTTAG TTCACTTTCA AATACTTTAA TTAAAAGGAC GAAAACGAAA 771 TTGGGGGTTT CCCCTATTGT TTGTCAAGAG TTTCGAGGAC GGCGTTTTTC TTGCTAAAAT CACAAGTATT AACCCCCAAA GGGGATAACA AACAGTTCTC AAAGCTCCTG CCGCAAAAAG AACGATTTTA GTGTTCATAA unc-54 3' UTR 841 GATGAGCACG ATGCAAGAAA GATCGGAAGA AGGTTTGGGT TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT CTACTCGTGC TACGTTCTTT CTAGCCTTCT TCCAAACCCA AACTCCGAGT CACCTTCCAC TCATCTTCAA 911 GATAATTTGA AAGTGGAGTA GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTC CCAATATACC CTATTAAACT TTCACCTCAT CACAGATACC CCAAAAACGG AATTTACTGT CTTATGTAAG GGTTATATGG unc-54 3' UTR 981 AAACATAACT GTTTCCTACT AGTCGGCCGT ACGGGCCCTT TCGTCTCGCG CGTTTCGGTG ATGACGGTGA TTTGTATTGA CAAAGGATGA TCAGCCGGCA TGCCCGGGAA AGCAGAGCGC GCAAAGCCAC TACTGCCACT

FIG. 5 (CONTINUED 1.)

	CGGATGCCGG GCCTACGGCC						1051
	CTATGCGGCA GATACGCCGT						1121
	AGGAGAAAAT TCCTCTTTTA						1191
	ATAATAATGG TATTATTACC						1261
	TTTTCTAAAT AAAAGATTTA						1331
amp			• •				
	AAAAAGGAAG TTTTTCCTTC						1401
amp	====================================	*2020006#22				,	
CTCACCCAGA	CCTGTTTTTG GGACAAAAAC	ATTTTGCCTT	TTTTTGCGGC	CTTATTCCCT	CCGTGTCGCC	TTCAACATTT	1471
amp						:=== = =====	
ACTGGATCTC	GTTACATCGA CAATGTAGCT	GCACGAGTGG	TCAGTTGGGT	ATGCTGAAGA	AAAGTAAAAG	AACGCTGGTG	1541
amp	*********					22000000000	
TTTAAAGTTC	GATGAGCACT CTACTCGTGA	GTTTTCCAAT	CCCGAAGAAC	GAGTTTTCGC	AGATCCTTGA	AACAGCGGTA	1611
amp						**********	
TACACTATTC	GGTCGCCGCA CCAGCGGCGT	AGAGCAACTC	ACGCCGGGCA	TCCCGTATTG	CGCGGTATTA	TGCTATGTGG	1681
amp			~				
AGTAAGAGAA	ATGGCATGAC TACCGTACTG	CATCTTACGG	CACAGAAAAG	ACTCACCAGT	TTGGTTGAGT	TCAGAATGAC	1751
amp		••					
ATCGGAGGAC	TCTGACAACG AGACTGTTGC	CÇAACTTACT	AACACTGCGG	CATGAGTGAT	CTGCCATAAC	TTATGCAGTG	1821
						amp	
GGGAACCGGA	CTTGATCGTT GAACTAGCAA	TGTAACTCGC	TGGGGGATCA	TTGCACAACA	AACCGCTTTT	CGAAGGAGCT	1891
						amp	
AACGTTGCGC	CAATGGCAAC	ATGCCTGTAG	TGACACCACG	ACGACGAGCG	GCCATACCAA	GCTGAATGAA	1961
TTGCAACGCG	GTTACCGTTG	TACGGACATC	ACTGTGGTGC	TGCTGCTCGC	CGGTATGGTT	CGACTTACTT	

FIG. 5 (CONTINUED 2.)

	атр						
2031	AAACTATTAA	CTGGCGAACT	ACTTACTCTA	GCTTCCCGGC	AACAATTAAT	AGACTGGATG TCTGACCTAC	GAGGCGGATA
	amp			1 # F T T T T T T T T T T T T T T T T T T			
2101						GCTGATAAAT CGACTATTTA	

2171						CCTCCCGTAT GGAGGGCATA	
	amp						
2241	TACACGACGG	GGAGTCAGGC	AACTATGGAT	GAACGAAATA	GACAGATCGC	TGAGATAGGT ACTCTATCCA	GCCTCACTGA
	amp	===					
2311	TTAAGCATTG	GTAACTGTCA				GATTTAAAAC CTAAATTTTG	
2381						TCCCTTAACG AGGGAATTGC	
2451	TTCCACTGAG AAGGTGACTC	CGTCAGACCC GCAGTCTGGG	CGTAGAAAAG GCATCTTTTC	ATCAAAGGAT TAGTTTCCTA	CTTCTTGAGA GAAGAACTCT	TCCTTTTTTT AGGAAAAAA	CTGCGCGTAA GACGCGCATT
2521						CCGGATCAAG GGCCTAGTTC	
2591						TCCTTCTAGT AGGAAGATCA	
2661						GCTAATCCTG CGATTAGGAC	
2731						TAGTTACCGG ATCAATGGCC	
2801						CGACCTACAC GCTGGATGTG	
2871						GGCGGACAGG CCGCCTGTCC	
2941						GCCTGGTATC CGGACCATAG	
3011						CAGGGGGGCG GTCCCCCCGC	
3081						TTTTGCTCAC AAAACGAGTG	
3151						GCTGATACCG CGACTATGGC	
3221	CCGAACGACC GGCTTGCTGG	GAGCGCAGCG CTCGCGTCGC	AGTCAGTGAG TCAGTCACTC	CGAGGAAGCG GCTCCTTCGC	GAAGAGCGCC CTTCTCGCGG	CAATACGCAA GTTATGCGTT	ACCGCCTCTC TGGCGGAGAG
3291						CTGGAAAGCG GACCTTTCGC	
3361						CACTTTATGC GTGAAATACG	TTCCGGCTCG AAGGCCGAGC
3431						ATGACCATGA TACTGGTACT	

F1G.6.

	T7 promoter	Outron
3		
1	AGCTTGGCGC CTAATACGAC TCACTATAGG GCTGCAGGTC GACTCTAGAT TACAACTAAT TATACTCGAACCGCG GATTATGCTG AGTGATATCC CGACGTCCAG CTGAGATCTA ATGTTGATTA ATATC	CTTATT GAATAA
	Outron synth. in	
71	TGAATATTCA AATTTTCAGA CCCGGGATTG GCCAAAGGAC CCAAAGGTAT GTTTCGAATG ATACTACTATAAAGT TTAAAAGTCT GGGCCCTAAC CGGTTTCCTG GGTTTCCATA CAAAGCTTAC TATGI	
	synth. intron A GFP with in	
141	AACATAGAAC ATTTTCAGGA GGACCCTTGG CTAGCGTCGA CGGTACCATG GGGCGCGCCA TGAGT TTGTATCTTG TAAAAGTCCT CCTGGGAACC GATCGCAGCT GCCATGGTAC CCCGCGCGGT ACTC	PAAAGG ATTTCC
	GPP with in	
211	AGAAGACTT TTCACTGGAG TTGTCCCAAT TCTTGTTGAA TTAGATGGTG ATGTTAATGG GCACATCTTCTTGAA AAGTGACCTC AACAGGGTTA AGAACAACTT AATGTACCAC TACAATTACC CGTG	TTTAAA PAAATTT
	GFP with in	
281	TCTGTCAGTG GAGAGGGTGA AGGTGATGCA ACATACGGAA AACTTACCCT TAAATTTATT TGCAC AGACAGTCAC CTCTCCCACT TCCACTACGT TGTATGCCTT TTGAATGGGA ATTTAAATAA ACGTC	
	GFP with ir	
351	GARARCTACC TGTTCCATGG GTARGTTTAR ACATATATAT ACTARCTARC CCTGATTATT TARAY CTTTTGATGG ACARGGTACC CATTCARATT IGTATATATA TGATTGATTG GGACTARTAR ATTTR	TTTCA VAAAGT
	GFP with in	
421	GCCAACACTT GTCACTACTT TETGTTATGG TGTTCAATGC TCTCGAGAT ACCCAGATCA TATGF CGGTTGTGAA CAGTGATGAA AGACAATACC ACAAGTTACG AAGAGCTCTA TGGGTCTAGT ATACT	
	GFP with in	
491	CATGACITTT TCAAGAGTGC CATGCCCGAA GGTTATGTAC AGGAAAGAAC TATATTTTTC AAAGAGTACTGAAAA AGTTCTCACG GTACGGGCTT CCAATACATG TCCTTTCTTG ATATAAAAAG TTTCT	TGACG TACTGC
	GFP with in	
561	GGAACTACAA GACACGTAAG TTTAAACAGT TCGGTACTAA CTAACCATAC ATATTTAAAT TTTCA CCTTGATGTT CTGTGCATTC AAATTTGTCA AGCCATGATT GATTGGTATG TATAAATTTA AAAGT	CCACG
	GFP with introns	
631	TGAAGTCAAG TTTGAAGGTG ATACCCTTGT TAATAGAATC GAGTTAAAAG GTATTGATTT TAAAG ACTICAGTTC AAACTICCAC TATGGGAACA ATTATCTTAG CTCAATTTTC CATAACTAAA ATTTC	AAGAT
	GFP with introns	
701	GGAAACATTC TTGGACACAA ATTGGAATAC AACTATAACT CACACAATGT ATACATCATG GCAGA CCTTTGTAAG AACCTGTGTT TAACCTTATG TTGATATTGA GTGTGTTACA TATGTAGTAC CGTCT	CAAAC
	GFP with introns	
771	AAAAGAATGG AATCAAAGTT GTAAGTTTAA ACTTGGACTT ACTAACTAAC GGATTATATT TAAATTTTCTTACC TTAGTTTCAA CATTCAAATT TGAACCTGAA TGATTGATTG CCTAATATAA ATTTA	TTTCA
	GFP with introns	
841	GAACTTCAAA ATTAGACACA ACATTGAAGA TGGAAGCGTT CAACTAGCAG ACCATTATCA ACAAA CTTGAAGTTT TAATCTGTGT TGTAACTTCT ACCTTCGCAA GTTGATCGTC TGGTAATAGT TGTTT	ATACT
	GFP with introns	
911	CCAATTGGCG ATGGCCCTGT CCTTTTACCA GACAACCATT ACCTGTCCAC ACAATCTGCC CTTTC GGTTAACCGC TACCGGGACA GGAAAATGGT CTGTTGGTAA TGGACAGGTG TGTTAGACGG GAAAG	GAAAG
	GFP with introns	
981	ATCCCARCGA AAAGAGAGAC CACATGGTCC TTCTTGAGTT TGTAACAGCT GCTGGGATTA CACAT TAGGGTTGCT TTTCTCTCTG GTGTACCAGG AAGAACTCAA ACATTGTCGA CGACCCTAAT GTGTA	GGCAT

FIG. 6 (CONTINUED 1.)

	GFP with in	ntrons				unc	-54 3	UTR
1051	GGATGAACTA CCTACTTGAT	TACAAATAGG ATGTTTATCC	GCCGGCCGAG CGGCCGGCTC	CTCCGCATCG GAGGCGTAGC	GCCGCTGTCA CGGCGACAGT	TCAGATCGCC AGTCTAGCGG	TAGAGO	GCGG
	********						-54 3	
1121	CGTGCCTCTG	ACTTCTAAGT TGAAGATTCA	CCAATTACTC	TTCAACATCC	CTACATGCTC	TTTCTCCCTG	TGCTC	CACC
					==========		-54 3	
1191	CCCTATTTTT	GTTATTATCA CAATAATAGT	AAAAAACTTC	TTCTTAATTT	CTTTGTTTTT	TAGCTTCTTT	TAAGTO	CACCT
			, ::::::::::::::::::::::::::::::::::::				-54 3	
1261		AATTGTGTAG TTAACACATC				TCAGCTTTTT	TTAACA	ACGAG
				*********			-54 3	
1331	CCTCCCCCA	AATAATAA TTATTATT	TTCTATCCCA AAGATAGGGŢ	AAATCTACAC TTTAGATGTG	AATGTTCTGT TTACAAGACA	CATGTGAAGA	ATACAZ	AAAA
							-54 3	UTR
1401		TAAATTTTTT ATTTAAAAAA						
	unc-54 3'	UTR			******			
1471	GTTTCAGTTT	ATGACCGCAA TACTGGCGTT	TTTTTATTTC	TTCGCACGTC	TGGGCCTCTC	ATGACGTCAA	ATCATO	CTCA
	unc-54 3'	UTR	- Medic 2 v z propi					
1541	TCGTGAAAAA	GTTTTGGAGT CAAAACCTCA	ATTTTTGGAA	TTTTTCAATC	AAGTGAAAGT	TTATGAAATT	AATTT	CCTG
	unc-54 3'	UTR	######======				======	
1611	CTTTTGCTTT	TTGGGGGTTT AACCCCCAAA	CCCCTATTGT	TTGTCAAGAG	TTTCGAGGAC	GGCGTTTTTC	TTGCT	TAAAA
	unc-54 3'	UTR		42-22-22-27	e s s s s s s s s s s s s s s s s s s s			
1681	CACAAGTATT GTGTTCATAA	GATGAGCACG CTACTCGTGC	ATGCAAGAAA TACGTTCTTT	GATCGGAAGA CTAGCCTTCT	AGGTTTGGGT TCCAAACCCA	TTGAGGCTCA AACTCCGAGT	GTGGAZ CACCT	AGGTG CCAC
	unc-54 3'	UTR						
1751	AGTAGAAGTT	GATAATTTGA CTATTAAACT	AAGTGGAGTA	GTGTCTATGG	GGTTTTTGCC	TTAAATGACA	GAATAG	CATTC
	unc-54 31	UTR						
1821	CCAATATACC	AAACATAACT TTTGTATTGA	GTTTCCTACT	AGTCGGCCGT TCAGCCGGCA	ACGGGCCCTT TGCCCGGGAA	TCGTCTCGCG AGCAGAGCGC	CGTTT(GGTG GCCAC
1891		AAACCTCTGA TTTGGAGACT						
1961	GAGCAGACAA CTCGTCTGTT	GCCCGTCAGG CGGGCAGTCC	GCGCGTCAGC CGCGCAGTCG	GGGTGTTGGC CCCACAACCG	GGGTGTCGGG CCCACAGCCC	GCTGGCTTAA CGACCGAATT	CTATGO	CGGCA SCCGT
2031	TCAGAGCAGA AGTCTCGTCT	TTGTACTGAG AACATGACTC	AGTGCACCAT TCACGTGGTA	ATGCGGTGTG TACGCCACAC	AAATACCGCA TTTATGGCGT	CAGATGCGTA GTCTACGCAT	AGGAGA TCCTCT	TAAAF ATTT
2101	ACCGCATCAG TGGCGTAGTC	GCGGCCTTAA CGCCGGAATT	GGGCCTCGTG CCCGGAGCAC	ATACGCCTAT TATGCGGATA	TTTTATAGGT AAAATATCCA	TAATGTCATG ATTACAGTAC	ATAATA TATTAT	AATGG PTACC

FIG. 6 (CONTINUED 2.)

	:						
2171		GTCAGGTGGC CAGTCCACCG					
2241		ATGTATCCGC TACATAGGCG					
	terr es;		.======================================		:#8 444==466:	12#2600000	qms
2311		TTCAACATTT AAGTTGTAAA					
	b	*****					qma
2381	CTCACCCAGA	AACGCTGGTG TTGCGACCAC	AAAGTAAAAG	ATGCTGAAGA	TCAGTTGGGT	GCACGAGTGG	GTTACATCGA
							amp
2451	ACTGGATCTC	AACAGCGGTA TTGTCGCCAT	AGATCCTTGA	GAGTTTTCGC	CCCGAAGAAC	GTTTTCCAAT	GATGAGCACT
							amp
2521	TTTAAAGTTC	TGCTATGTGG ACGATACACC	CGCGGTATTA	TCCCGTATTG	ACGCCGGGCA	AGAGCAACTC	GGTCGCCGCA
							amp
2591		TCAGAATGAC					
		AGTCTTACTG					TACCGTACTG
			:22::52:22:				qms ==========
2661		TTATGCAGTG AATACGTCAC					
		amp					
2731	ATCGGAGGAC	CGAAGGAGCT GCTTCCTCGA	AACCGCTTTT	TTGCACAACA	TGGGGGATCA	TGTAACTCGC	CTTGATCGTT
	атр						
2801	GGGAACCGGA	GCTGAATGAA CGACTTACTT	GCCATACCAA	ACGACGAGCG	TGACACCACG	ATGCCTGTAG	CAATGGCAAC
	amp						
2871	AACGTTGCGC	AAACTATTAA TTTGATAATT	CTGGCGAACT GACCGCTTGA	ACTTACTCTA	GCTTCCCGGC	AACAATTAAT	AGACTGGATG
	amp		; 1				
2941		AAGTTGCAGG					
		TTCAACGTCC					
	amp						
3011	CTGGAGCCGG	TGAGCGTGGG ACTCGCACCC	TCTCGCGGTA	TCATTGCAGC	ACTGGGGCCA	GATGGTAAGC	CCTCCCGTAT
	amp				•		
3081		TACACGACGG					
		ATGTGCTGCC					

FIG. 6 (CONTINUED 3.)

	amp		===				
3151	GCCTCACTGA	TTAAGCATTG AATTCGTAAC	GTAACTGTCA	GACCAAGTTI CTGGTTCAAA	ACTCATATAT TGAGTATATA	ACTTTAGATT TGAAATCTAA	GATTTAAAAC CTAAATTTTG
3221	TTCATTTTTA AAGTAAAAAT	ATTTAAAAGG	ATCTAGGTGA TAGATCCACT	AGATCCTTTT TCTAGGAAAA	TGATAATCTC ACTATTAGAG	ATGACCAAAA TACTGGTTTT	TCCCTTAACG AGGGAATTGC
3291	TGAGTTTTCG	TTCCACTGAG	CGTCAGACCC	CGTAGAAAAG	ATCAAAGGAT	CTTCTTGAGA	TCCTTTTTTT
	ACTCAAAAGC	AAGGTGACTC	GCAGTCTGGG	GCATCTTTC	TAGTTTCCTA	GAAGAACTCT	AGGAAAAAA
3361		TCTGCTGCTT AGACGACGAA					
3431		TCTTTTTCCG AGAAAAAGGC					
3501		TTAGGCCACC AATCCGGTGG					
3571	TTACCAGTGG	CTGCTGCCAG	TGGCGATAAG	TCGTGTCTTA	CCGGGTTGGA	CTCAAGACGA	TAGTTACCGG
	AATGGTCACC	GACGACGGTC	ACCGCTATTC	AGCACAGAAT	GGCCCAACCT	GAGTTCTGCT	ATCAATGGCC
3641	ATAAGGCGCA	GCGGTCGGGC	TGAACGGGGG	GTTCGTGCAC	ACAGCCCAGC	TTGGAGCGAA	CGACCTACAC
	TATTCCGCGT	CGCCAGCCCG	ACTTGCCCCC	CAAGCACGTG	TGTCGGGTCG	AACCTCGCTT	GCTGGATGTG
3711	CGAACTGAGA	TACCTACAGC	GTGAGCATTG	AGAAAGCGCC	ACGCTTCCCG	AAGGGAGAAA	GGCGGACAGG
	GCTTGACTCT	ATGGATGTCG	CACTCGTAAC	TCTTTCGCGG	TGCGAAGGGC	TTCCCTCTTT	CCGCCTGTCC
3781 .	TATCCGGTAA	GCGGCAGGGT	CGGAACAGGA	GAGCGCACGA	GGGAGCTTCC	AGGGGGAAAC	GCCTGGTATC
	ATAGGCCATT	CGCCGTCCCA	GCCTTGTCCT	CTCGCGTGCT	CCCTCGAAGG	TCCCCCTTTG	CGGACCATAG
3851	TTTATAGTCC	TGTCGGGTTT	CGCCACCTCT	GACTTGAGCG	TCGATTTTTG	TGATGCTCGT	CAGGGGGGGG
	AAATATCAGG	ACAGCCCAAA	GCGGTGGAGA	CTGAACTCGC	AGCTAAAAAC	ACTACGAGCA	GTCCCCCCGC
3921	GAGCCTATGG	AAAAACGCCA	GCAACGCGGC	CTTTTTACGG	TTCCTGGCCT	TTTGCTGGCC	TTTTGCTCAC
	CTCGGATACC	TTTTTGCGGT	CGTTGCGCCG	GAAAAATGCC	AAGGACCGGA	AAACGACCGG	AAAACGAGTG
3991	ATGTTCTTTC	CTGCGTTATC	CCCTGATTCT	GTGGATAACC	GTATTACCGC	CTTTGAGTGA	GCTGATACCG
	TACAAGAAAG	GACGCAATAG	GGGACTAAGA	CACCTATTGG	CATAATGGCG	GAAACTCACT	CGACTATGGC
4061	CTCGCCGCAG	CCGAACGACC	GAGCGCAGCG	AGTCAGTGAG	CGAGGAAGCG	GAAGAGCGCC	CAATACGCAA
	GAGCGGCGTC	GGCTTGCTGG	CTCGCGTCGC	TCAGTCACTC	GCTCCTTCGC	CTTCTCGCGG	GTTATGCGTT
4131	ACCGCCTCTC	CCCGCGCGTT	GGCCGATTCA	TTAATGCAGC	TGGCACGACA	GGTTTCCCGA	CTGGAAAGCG
	TGGCGGAGAG	GGGCGCGCAA	CCGGCTAAGT	AATTACGTCG	ACCGTGCTGT	CCAAAGGGCT	GACCTTTCGC
4201	GGCAGTGAGC	GCAACGCAAT	TAATGTGAGT	TAGCTCACTC	ATTAGGCACC	CCAGGCTTTA	CACTTTATGC
	CCGTCACTCG	CGTTGCGTTA	ATTACACTCA	ATCGAGTGAG	TAATCCGTGG	GGTCCGAAAT	GTGAAATACG
4271	TTCCGGCTCG	TATGTTGTGT	GGAATTGTGA	GCGGATAACA	ATTTCACACA	GGAAACAGCT	ATGACCATGA
	AAGGCCGAGC	ATACAACACA	CCTTAACACT	CGCCTATTGT	TAAAGTGTGT	CCTTTGTCGA	TACTGGTACT
4341	TTACGCCA AATGCGGT		•				•

` 4 . g . . .

1

SEQUENCE LISTING

```
<110> DEVGEN NV
<120> GENE EXPRESSION SYSTEM
<130> SCB/55177/001
<140>
<141>
<160> 5
<170> PatentIn Ver. 2.0
<210> 1
<211> 47
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence:
      oligonucleotide o-GN59
<400> 1
                                                                   47
ctagattaca actaattata cttatttgaa tattcaaatt ttcagac
<210> 2
<211> 47
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
     oligonucleotide o-GN60
<400> 2
                                                                   47
ccgggtctga aaatttgaat attcaaataa gtataattag ttgtaat
<210> 3
<211> 3498
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: plasmid
      pDW3123
<400> 3
agettggege etaataegae teactatagg getgeaggte gaetetagat tacaactaat 60
tatacttatt tgaatattca aattttcaga cccgggattg gccaaaggac ccaaaggtat 120
gtttcgaatg atactaacat aacatagaac attttcagga ggaccettgg ctagcgtcct 180
gctgggatta cacatggcat ggatgaacta tacaaatagg gccggccgag ctccgcatcg 240
geogetytea teagategee atetegegee egtgeetetg acttetaagt ceaattacte 300
ttcaacatcc ctacatgete ttteteeetg tgeteecace ecctatttt gttattatea 360
aaaaaactto ttottaattt otttgttttt tagottottt taagtcacct otaacaatga 420
aattgtgtag attcaaaaat agaattaatt cgtaataaaa agtcgaaaaa aattgtgctc 480
cctccccca ttaataataa ttctatccca aaatctacac aatgttctgt gtacacttct 540
tatgtttttt ttacttctga taaatttttt ttgaaacatc atagaaaaaa ccgcacacaa 600
aataccttat catatgttac gtttcagttt atgaccgcaa tttttatttc ttcgcacgtc 660
tgggcctctc atgacgtcaa atcatgctca tcgtgaaaaa gttttggagt atttttggaa 720
```

- 1

```
titttcaatc aagtgaaagt tiatgaaatt aattitcctg citttgctit tigggggttt 780
cccctattgt ttgtcaagag tttcgaggac ggcgtttttc ttgctaaaat cacaagtatt 840
gatgagcacg atgcaagaaa gatcggaaga aggtttgggt ttgaggctca gtggaaggtg 900
agtagaagtt gataatttga aagtggagta gtgtctatgg ggtttttgcc ttaaatgaca 960
gaatacatte ccaatatace aaacataact gttteetact agteggeegt aegggeeett 1020
togtotogog ogtttoggtg atgacggtga aaacototga cacatgcago tocoggagao 1080
ggtcacaget tgtctgtaag eggatgeegg gageagaeaa geeegteagg gegegteage 1140
gggtgttggc gggtgtcggg gctggcttaa ctatgcggca tcagagcaga ttgtactgag 1200
agtgcaccat atgcggtgtg aaataccgca cagatgcgta aggagaaaat accgcatcag 1260
gcggccttaa gggcctcgtg atacgcctat ttttataggt taatgtcatg ataataatgg 1320
tttcttagac gtcaggtggc acttttcggg gaaatgtgcg cggaacccct atttgtttat 1380
ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga taaatgcttc 1440
aataatattg aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc cttattccct 1500
tttttgcggc attttgcctt cctgtttttg ctcacccaga aacgctggtg aaagtaaaag 1560
atgetgaaga teagttgggt geacgagtgg gttacatega aetggatete aacageggta 1620
agateettga gagttttege eeegaagaac gtttteeaat gatgageact tttaaagtte 1680
tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc ggtcgccgca 1740
tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag catcttacgg 1800
atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat aacactgcgg 1860
ccaacttact totgacaacg atoggaggac cgaaggaget aaccgctttt ttgcacaaca 1920
tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa gccataccaa 1980
acgacgageg tgacaccacg atgcctgtag caatggcaac aacgttgcgc aaactattaa 2040
ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg gaggcggata 2100
augttgcagg accaettetg egeteggeee tteeggetgg etggtttatt getgataaat 2160
ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca gatggtaagc 2220
cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat gaacgaaata 2280
gacagatege tgagataggt gcctcactga ttaagcattg gtaactgtca gaccaagttt 2340
actcatatat actttagatt gatttaaaac ttcatttta atttaaaagg atctaggtga 2400
agateetttt tgataatete atgaceaaaa teeettaaeg tgagtttteg tteeaetgag 2460
cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tcctttttt ctgcgcgtaa 2520
tctgctgctt gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg ccggatcaag 2580
agctaccaac tottttccg aaggtaactg gottcagcag agcgcagata ccaaatactg 2640
tccttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca ccgcctacat 2700
acctcgctct gctaatcctg ttaccagtgg ctgctgccag tggcgataag tcgtgtctta 2760
ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc tgaacggggg 2820
gttcgtgcac acagcccage ttggagegaa egacetacae egaactgaga tacetacage 2880
gtgagcattg agaaagcgcc acgcttcccg aagggagaaa ggcggacagg tatccggtaa 2940
gcggcagggt cggaacagga gagcgcacga gggagcttcc agggggaaac gcctggtatc 3000
tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg tgatgctcgt 3060
caggggggcg gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct 3120
tttgctggcc ttttgctcac atgttctttc ctgcgttatc ccctgattct gtggataacc 3180
gtattaccgc ctttgagtga gctgataccg ctcgccgcag ccgaacgacc gagcgcagcg 3240
agtcagtgag cgaggaagcg gaagagegee caatacgcaa accgeetete eccgegegtt 3300
ggccgattca ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc 3360
gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta cactttatgc 3420
ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca ggaaacagct 3480
atgaccatga ttacgcca
                                                                  3498
<210> 4
<211> 4348
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: plasmid
     pDW3124
<400> 4
agettggege ctaatacgae teactatagg getgeaggte gaetetagat tacaactaat 60
tatacttatt tgaatattca aattttcaga cccgggattg gccaaaggac ccaaaggtat 120
gtttcgaatg atactaacat aacatagaac attttcagga ggaccettgg ctagegtega 180
```

4. . .

cggtaccatg gggcgcgcca tgagtaaagg agaagaactt ttcactggag ttgtcccaat 240 tettgttgaa ttagatggtg atgttaatgg geacaaattt tetgteagtg gagagggtga 300 aggtgatgca acatacggaa aacttaccct taaatttatt tgcactactg gaaaactacc 360 tgttccatgg gtaagtttaa acatatatat actaactaac cctgattatt taaattttca 420 gccaacactt gtcactactt totgttatgg tgttcaatgc ttotogagat acccagatca 480 tatgaaacgg catgactttt tcaagagtgc catgcccgaa ggttatgtac aggaaagaac 540 tatattttte aaagatgacg ggaactacaa gacacgtaag tttaaacagt tcggtactaa 600 ctaaccatac atatttaaat tttcaggtgc tgaagtcaag tttgaaggtg atacccttgt 660 taatagaatc gagttaaaag gtattgattt taaagaagat ggaaacattc ttggacacaa 720 attggaatac aactataact cacacaatgt atacatcatg gcagacaaac aaaagaatgg 780 aatcaaagtt gtaagtttaa acttggactt actaactaac ggattatatt taaattttca 840 gaacttcaaa attagacaca acattgaaga tggaagcgtt caactagcag accattatca 900 acaaaatact ccaattggcg atggccctgt ccttttacca gacaaccatt acctgtccac 960 acaatctgcc ctttcgaaag atcccaacga aaagagagac cacatggtcc ttcttgagtt 1020 tgtaacaget getgggatta cacatggeat ggatgaacta tacaaatagg geeggeegag 1080 ctocgcateg geogetytea teagategee atotegegee cytycetety acttotaagt 1140 ccaattactc ttcaacatcc ctacatgctc tttctccctg tgctcccacc ccctattttt 1200 gttattatca aaaaaacttc ttcttaattt ctttgttttt tagcttcttt taagtcacct 1260 ctaacaatga aattgtgtag attcaaaaat agaattaatt cgtaataaaa agtcgaaaaa 1320° aattgtgctc cctcccccca ttaataataa ttctatccca aaatctacac aatgttctgt 1380 gtacacttct tatgtttttt ttacttctga taaatttttt ttgaaacatc atagaaaaa 1440 ccgcacacaa aataccttat catatgttac gtttcagttt atgaccgcaa tttttatttc 1500 ttcgcacgtc tgggcctctc atgacgtcaa atcatgctca tcgtgaaaaa gttttggagt 1560 atttttggaa tttttcaatc aagtgaaagt ttatgaaatt aattttcctg cttttgcttt 1620 ttggggggttt cccctattgt ttgtcaagag tttcgaggac ggcgtttttc ttgctaaaat 1680 cacaagtatt gatgagcacg atgcaagaaa gatcggaaga aggtttgggt ttgaggctca 1740 gtggaaggtg agtagaagtt gataatttga aagtggagta gtgtctatgg ggtttttgcc 1800 ttaaatgaca gaatacatto ocaatataco aaacataact gtttootact agtoggoogt 1860 acgggccctt tcgtctcgcg cgtttcggtg atgacggtga aaacctctga cacatgcagc 1920 tcccggagac ggtcacagct tgtctgtaag cggatgccgg gagcagacaa gcccgtcagg 1980 gegegteage gggtgttgge gggtgteggg getggettaa etatgeggea teagageaga 2040 ttgtactgag agtgcaccat atgcggtgtg aaataccgca cagatgcgta aggagaaaat 2100 accgcatcag gcggccttaa gggcctcgtg atacgcctat ttttataggt taatgtcatg 2160 ataataatgg tttcttagac gtcaggtggc acttttcggg gaaatgtgcg cggaacccct 2220 atttgtttat ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga 2280 taaatgette aataatattg aaaaaggaag agtatgagta tteaacattt cegtgtegee 2340 cttattccct tttttgcggc attttgcctt cctgtttttg ctcacccaga aacgctggtg 2400 aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc 2460 aacageggta agateettga gagttttege eeegaagaac gtttteeaat gatgageaet 2520 tttaaagttc tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc 2580 ggtcgccgca tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag 2640 catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat 2700 aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt 2760 ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa 2820 gccataccaa acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgcgc 2880 aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg 2940 gaggcggata aagttgcagg accaettetg egeteggeee tteeggetgg etggtttatt 3000 gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca 3060 gatggtaagc cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat 3120 gaacgaaata gacagatege tgagataggt geeteaetga ttaagcattg gtaactgtea 3180 gaccaagttt actcatatat actttagatt gatttaaaac ttcattttta atttaaaagg 3240 atctaggtga agateetttt tgataatete atgaccaaaa teeettaaeg tgagtttteg 3300 ttccactgag cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tcctttttt 3360 ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg 3420 ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata 3480 ccaaatactg teettetagt gtageegtag ttaggeeacc aetteaagaa etetgtagea 3540 ecgectacat acctegetet getaateetg ttaccagtgg etgetgecag tggegataag 3600 tegtgtetta eegggttgga eteaagaega tagttaeegg ataaggegea geggteggge 3660 tgaacggggg gttcgtgcac acageccage ttggagegaa egaectacae egaactgaga 3720 tacctacage qtgageattg agaaagegee acgetteeeg aagggagaaa ggeggaeagg 3780 tatccggtaa gcggcagggt cggaacagga gagcgcacga gggagcttcc agggggaaac 3840

```
gcctggtatc tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg 3900
tgatgctcgt caggggggcg gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg 3960
ttcctggcct tttgctggcc ttttgctcac atgttctttc ctgcgttatc ccctgattct 4020
gtggataacc gtattaccgc ctttgagtga gctgataccg ctcgccgcag ccgaacgacc 4080
gagogoagog agtoagtgag ogaggaagog gaagagogoo caataogoaa acogoototo 4140
eccgcgcgtt ggccgattca ttaatgcage tggcacgaca ggtttcccga ctggaaagcg 4200
ggcagtgage gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta 4260
cactttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca 4320
ggaaacagct atgaccatga ttacgcca
<210> 5
<211> 9309
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: plasmid pGN148
<400> 5
atgactgctc caaagaagaa gcgtaaggta ccggtaatga acacgattaa catcgctaag 60
aacgactict cigacatega aciggetget alecceptica acactetgge igaccattae 120
ggtgagcgtt tagctcggta agtttaaaca tctagatact aactaacgat taacatttaa 180
attiticaging aacagitigge cettingangeat gangtettaen angaingning and ancangettic 240
cgcaagatgt ttgagcgtca acttaaagct ggtgaggttg cggataacgc tgccgccaag 300
cctctcatca ctaccctact ccctaagatg attgcacgca tcaacgactg gtttgaggaa 360
gtgaaagcta agcgcggcaa gcgcccgaca gccttccagt tcctgcaaga aatcaagccg 420
gaageegtag egtacateae eattaagace actetggett geetaaceag tgetgacaat 480
acaacegtte aggetgtage aagegeaate ggtegggeea ttgaggaega ggetegette 540
ggtcgtatcc gtgaccttga agctaagcac ttcaagaaaa acgttgagga acaactcaac 600
aagegegtag ggeaegteta caagaaagea tttatgeaag ttgtegagge tgaeatgete 660
tctaagggtc tactcggtgg cgaggcgtgg tcttcgtggc ataaggaaga ctctattcat 720
gtaggagtac gctgcatcga gatgctcatt gagtcaaccg gagtggttag cttacaccgc 780
caaaatgctg gcgtagtagg tcaagactct gagactatcg aactcgcacc tgaatacgct 840
gaggetateg caaccegtge aggtgegetg getggeatet etcegatgtt ccaaccttge 900
gtagttcctc ctaagcogtg gactggcatt actggtggtg gctattgggc taacggtcgt 960 cgtcctctgg cgctggtgcg tactcacagt aagaaagcac tgatgcgcta cgaagacgtt 1020
tacatgeetg aggtgtacaa agegattaae attgegeaaa acaeegeatg gaaaateaae 1080
aagaaagtcc tagcggtcgc caacgtaatc accaagtgga agcattgtcc ggtcgaggac 1140
atccctgcga ttgagcgtga agaactcccg atgaaaccgg aagacatcga catgaatcct 1200
gaggetetea eegegtggaa aegtgetgee getgetgtgt aeegeaagga eaaggetege 1260
aagtetegee gtateageet tgagtteatg ettgageaag eeaataagtt tgetaaceat 1320
aaggccatet ggttccctta caacatggac tggcgcggtc gtgtttacgc tgtgtcaatg 1380
ttcaacccgc aagctaacga tatgaccaaa ggactgctta cgctggcgaa aggtaaacca 1440
atcggtaagg aaggttacta ctggctgaaa atccacggtg caaactgtgc gggtgtcgat 1500
aaggttoogt toootgagog catcaagtto attgaggaaa accaogagaa catcatggot 1560
tgegetaagt etecaetgga gaacaettgg tgggetgage aagattetee gttetgette 1620
cttgcgttct gctttgagta cgctggggta cagcaccacg gcctgagcta taactgctcc 1680
cttccgctgg cgtttgacgg gtcttgctct ggcatccagc acttctccgc gatgctccga 1740
gatgaggtag gtggtcgcgc ggttgtaagt ttaaactcta tcctactaac taacqaagct 1800
tatttaaatt ticagaactt getteetagt gaaacegtte aggacateta egggattgtt 1860
gctaagaaag tcaacgagat tctacaagca gacgcaatca atgggaccga taacgaagta 1920
gttaccgtga ccgatgagaa cactggtgaa atctctgaga aagtcaagct gggcactaag 1980
gcactggctg gtcaatggct ggcttacggt gttactcgca gtgtgactaa gcgttcagtc 2040
atgacgctgg cttacgggtc caaagagttc ggcttccgtc aacaagtgct ggaagatacc 2100
attcagccag ctattgattc cggcaagggt ctgatgttca ctcagccgaa tcaggctgct 2160
ggatacatgg ctaagctgat ttgggaatct gtgagcgtga cggtggtagc tgcggttgaa 2220
gcaatgaact ggcttaagtc tgctgctaag ctgctggctg ctgaggtcaa agataagaag 2280
actggagaga ttettegeaa gegttgeget gtgeattggg teacteegga tggttteeet 2340
gtgtggcagg aatacaagaa gcctattcaa acgcgtttga acctgatgtt cctcggtcag 2400
ttccgcttac agcctaccat taacaccaac aaagatagcg agattgatgc acacaaacag 2460
gagtetggta tegeteetaa etttgtacae ageeaagaeg gtageeacet tegtaagaet 2520
```

gtagtgtggg cacacgagaa gtacggaatc gaatcttttg cactgattca cgactccttc 2580 ggtaccattc cggctgacgc tgcgaacctg ttcaaagcag tgcgcgaaac tatggttgac 2640 acatatgagt cttgtgatgt actggctgat ttctacgacc agttcgctga ccagttgcac 2700 gagteteaat tggacaaaat gecagcactt ceggetaaag gtaacttgaa ceteegtgac 2760 atcttagagt cggacttcgc gttcgcgtaa gaattccaac tgagcgccgg tcgctaccat 2820 taccaacttg tetggtgtca aaaataatag gggeegetgt catcagagta agtttaaact 2880 gagttetact aactaacgag taatatttaa attttcagca tetegegeee gtgeetetga 2940 cttctaagtc caattactct tcaacatccc tacatgctct ttctccctgt gctcccaccc 3000 cctatttttg ttattatcaa aaaaacttct tcttaatttc tttgtttttt agcttctttt 3060 aagtcacctc taacaatgaa attgtgtaga ttcaaaaata gaattaattc gtaataaaaa 3120 gtcgaaaaaa attgtgctcc ctcccccat taataataat tctatcccaa aatctacaca 3180 atgttctgtg tacacttctt atgttttttt tacttctgat aaattttttt tgaaacatca 3240 tagaaaaaac cgcacacaaa ataccttatc atatgttacg tttcagttta tgaccgcaat 3300 ttttatttct tcgcacgtct gggcctctca tgacgtcaaa tcatgctcat cgtgaaaaag 3360 ttttggagta tttttggaat ttttcaatca agtgaaagtt tatgaaatta attttcctgc 3420 ttttgctttt tgggggtttc ccctattgtt tgtcaagagt ttcgagqacg gcgtttttct 3480 tgctaaaatc acaagtattg atgagcacga tgcaagaaag atcggaagaa ggtttgggtt 3540 tgaggctcag tggaaggtga gtagaagttg ataatttgaa agtggagtag tgtctatggg 3600 gtttttgcct taaatgacag aatacattcc caatatacca aacataactg tttcctacta 3660 gteggeegta egggeeettt egtetegege gttteggtga tgaeggtgaa aacetetgae 3720 acatgcaget eceggagaeg gteacagett gtetgtaage ggatgeeggg ageagaeaag 3780 ecegteaggg egegteageg ggtgttggeg ggtgtegggg etggettaac tatgeggeat 3840 cagagcagat tgtactgaga gtgcaccata tgcggtgtga aataccgcac agatgcgtaa 3900 ggagaaaata ccgcatcagg cggccttaag ggcctcgtga tacgcctatt titataggtt 3960 aatgtcatga taataatggt ttettagaeg teaggtggea ettttegggg aaatgtgege 4020 ggaaccccta tttgtttatt tttctaaata cattcaaata tgtatccgct catgagacaa 4080 taaccctgat aaatgcttca ataatattga aaaaggaaga gtatgagtat tcaacatttc 4140 cgtgtcgccc ttattccctt ttttgcggca ttttgccttc ctgtttttgc tcacccagaa 4200 acgctggtga aagtaaaaga tgctgaagat cagttgggtg cacgagtggg ttacatcgaa 4260 ctggatctca acageggtaa gatcettgag agttttegee eegaagaaeg ttttecaatg 4320 atgageaett ttaaagttet getatgtgge geggtattat eeegtattga egeegggeaa 4380 gagcaacteg gtegeegeat acactattet eagaatgaet tggttgagta etcaceagte 4440 acagaaaage atettaegga tggeatgaea gtaagagaat tatgeagtge tgeeataace 4500 atgagtgata acactgcggc caacttactt ctgacaacga tcggaggacc gaaggagcta 4560 acceptittt tgcacaacat gggggatcat gtaactegee tigategitg ggaaceggag 4620 ctgaatgaag ccataccaaa cgacgagcgt gacaccacga tgcctgtagc aatggcaaca 4680 acgttgcgca aactattaac tggcgaacta cttactctag cttcccggca acaattaata 4740 gactggatgg aggcggataa agttgcagga ccacttctgc gctcggccct tccggctggc 4800 tggtttattg ctgataaatc tggagccggt gagcgtgggt ctcgcggtat cattgcagca 4860 ctggggccag atggtaagec etecegtate gtagttatet acaegaeggg gagteaggea 4920 actatggatg aacgaaatag acagatcgct gagataggtg cctcactgat taagcattgg 4980 taactgtcag accaagttta ctcatatata ctttagattg atttaaaact tcatttttaa 5040 tttaaaagga tctaggtgaa gatccttttt gataatctca tgaccaaaat cccttaacgt 5100 gagttttegt tecaetgage gteagaeeee gtagaaaaga teaaaggate ttettgagat 5160 cctttttttc tgcgcgtaat ctgctgcttg caaacaaaaa aaccaccgct accagcggtg 5220 gtttgtttgc cggatcaaga gctaccaact ctttttccga aggtaactgg cttcagcaga 5280 gogoagatac caaatactgt cottotagtg tagoogtagt taggocacca ottoaagaac 5340 tetgtageae egectaeata ectegetetg etaateetgt taceagtgge tgetgeeagt 5400 ggcgataagt cgtgtcttac cgggttggac tcaagacgat agttaccgga taaggcgcag 5460 cggtcgggct gaacgggggg ttcgtgcaca cagcccagct tggagcgaac gacctacacc 5520 gaactgagat acctacageg tgageattga gaaagegeea egetteeega agggagaaag 5580 geggaeaggt ateeggtaag eggeagggte ggaacaggag agegeaegag ggagetteea 5640 gggggaaacg cotggtatot ttatagtoot gtogggttto gocacototg acttgagogt 5700 cgatttttgt gatgetegte aggggggegg ageetatgga aaaacgeeag caacgeggee 5760 tttttacggt tcctggcctt ttgctggcct tttgctcaca tgttctttcc tgcgttatcc 5820 cotgattotg tggataaccg tattaccgcc tttgagtgag ctgataccgc tcgccgcagc 5880 cgaacgaccg agcgcagcga gtcagtgagc gaggaagcgg aagagcgccc aatacgcaaa 5940 cogcetetee cogegogtty geogatteat taatgeaget ggeacgacag gtttecogae 6000 tggaaagegg geagtgageg caaegeaatt aatgtgagtt ageteaetea ttaggeaeee 6060 caggetttae aetttatget teeggetegt atgttgtgtg gaattgtgag eggataacaa 6120 tttcacacag gaaacagcta tgaccatgat tacgccaagc tgtaagttta aacatgatct 6180

· tactaactaa ctattctcat ttaaattttc agagettaaa aatggetgaa ateaeteaea 6240 acgatggata cgctaacaac ttggaaatga aataagcttg catgcctgca gagcaaaaaa 6300 atactgettt teettgeaaa atteggtget ttetteaaag agaaactttt gaagteggeg 6360 cgagcattte ettettgae ttetetett eegecaaaaa geetageatt tttattgata 6420 atttgattac acacactcag agttcttcga catgataaag tgtttcattg gcactcgccc 6480 taacagtaca tgacaagggc ggattattat cgatcgatat tgaagacaaa ctccaaatgt 6540 gtgctcattt tggagccccg tgtggggcag ctgctctcaa tatattacta gggagacgag 6600 gagggggace ttategaaeg tegeatgage cattettet tetttatgea etetetteae 6660 tototoacae attaatogat toatagacto coatattoot tgatgaaggt gtgggttttt 6720 agcttttttt cccgatttgt aaaaggaaga ggctgacgat gttaggaaaa agagaacgga 6780 gccgaaaaaa catccgtagt aagtcttcct tttaagccga cactttttag acagcattcg 6840 ccgctagttt tgaagtttaa attttaaaaa ataaaaatta gtttcaattt tttttaatta 6900 ctaaataggc aaaagttttt tcaagaactc tagaaaaact agcttaattc atgggtacta 6960 gaaaaattct tgttttaaat ttaatattta tcttaagatg taattacgag aagctttttt 7020 gaaaattoto aattaaaaga atttgoogat ttagaataaa agtottoaga aatgagtaaa 7080 ageteaaatt agaagtttgt tittaaagga aaaacaegaa aaaagaacae tatttatett 7140 ttcctccccg cgtaaaatta gttgttgtga taatagtgat ccgctgtcta tttgcactcg 7200 gctcttcaca ccgtgcttcc tctcacttga cccaacagga aaaaaaaaca tcacgtctga 7260 gacggtgaat tgccttatca agagcgtcgt ctctttcacc cagtaacaaa aaaaatttgg 7320 tttctttact ttatatttat gtaggtcaca aaaaaaaagt gatgcagttt tgtgggtcgg 7380 ttgtctccac accacctccg cctccagcag cacacaatca tcttcgtgtg ttctcgacga 7440 ttccttgtat gccgcggtcg tgaatgcacc acattcgacg cgcaactaca caccacactc 7500 acttteggtg gtattactae acgteategt tgttegtagt etecegetet ttegteecea 7560 ctcactcctc attattcccc ttggtgtatt gattttttt aaatggtaca ccactcctga 7620 cgtttctacc ttcttgtttt ccgtccattt agattttatc tggaaatttt tttaaaattt 7680 taggccagag agttctagtt cttgttctaa aagtctaggt cagacataca ttttctattt 7740 ctcatcaaaa aaaaagttga taaagaaaac tggttattca gaaagagtgt gtctcgttga 7800 aattgattca aaaaaaatt cccacccctc gcttgtttct caaaatatga gatcaacgga 7860 ttttttcctt ctcgattcaa ttttttgctg cgctctgtct gccaaagtgt gtgtgtccga 7920 gcaaaagatg agagaattta caaacagaaa tgaaaaaaag ttggccaaat aatgaagttt 7980 tatccgagat tgatgggaaa gatattaatg ttctttacgg tttggagggg agagagat 8040 agattttcgc atcaaactcc gccttttaca tgtcttttag aatctaaaat agatttttct 8100 catcattttt aatagaaaat cgagaaatta cagtaatttc gcaattttct tgccaaaaat 8160 acacqaaatt tgtgggtctc gccacqatct cggtcttagt ggttcatttg gtttaaaagt 8220 ttataaaatt tcaaattcta gtgtttaatt tccgcataat tggacctaaa atgggttttt 8280 gtcatcattt tcaacaagaa atcgtgaaaa tcctgttgtt tcgcaatttt cttttcaaaa 8340 atacacgaaa tatatggtaa tttcccgaaa tattgagggt ctcgccacga tttcagtcac 8400 agtggccagg atttatcacg aaaaaagttc gcctagtctc acatttccgg aaaaccgaat 8460 ctaaattagt tttttgtcat cattttgaac aaaaaatcga gacatcccta tagtttcgca 8520 attttcgtcg cttttctctc caaaaatgac agtctagaat taaaattcgc tggaactggg 8580 accatgatat cttttctccc cgtttttcat tttattttt attacactgg attgactaaa 8640 ggtcaccacc accgccagtg tgtgccatat cacacacaca cacacacaca atgtcgagat 8700 tttatgtgtt atcoctgctt gatttcgttc cgttgtctct ctctctctat tcatcttttg 8760 agccgagaag ctccagagaa tggagcacac aggatcccgg cgcgcgatgt cgtcgggaga 8820 tggcgccgcc tgggaagccg ccgagagata tcagggaaga tcgtctgatt tctcctcgga 8880 tgccacctca tctctcgagt ttctccgcct gttactccct gccgaacctg atatttcccg 8940 ttgtcgtaaa gagatgttt tatttactt tacaccgggt cctctctct tgccagcaca 9000 geteagtgtt ggetgtgtge tegggeteet gecaeeggeg geeteatett ettettette 9060 tteteteetg etetegetta teaettette atteattett atteetttte ateateaae 9120 tagcatttct tactttattt attttttca attttcaatt ttcagataaa accaaactac 9180 ttgggttaca gccgtcaaca gatccccggg attggccaaa ggacccaaag gtatgtttcg 9240 aatgatacta acataacata gaacatttte aggaggacce ttgettggag ggtacegage 9300 tcagaaaaa

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 22 November 2001 (22.11.2001)

PCT

(10) International Publication Number WO 01/88114 A3

(51) International Patent Classification7: C12N 15/00

(21) International Application Number: PCT/EP01/05794

(22) International Filing Date: 18 May 2001 (18.05.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0012231.7

19 May 2000 (19.05.2000) GI

- (71) Applicant (for all designated States except US): DEV-GEN NV [BE/BE]; Technologiepark 9. B-9052 Zwijnaarde (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PLAETINCK, Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). RENARD, Jean-Pierre [BE/BE]; Peter Benoitlaan 141, B-9050 Gentbrugge (BE). MORTIER, Katherine [BE/BE]; Lange Boomgaardstraat 25, B- Gent (BE). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Konrijk (BE).
- (74) Agent: BOULT WADE TENNANT; Verulam Gardens, 70 Gray's Inn Road, London WCIX 8BT (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH. GM. KE. LS. MW. MZ. SD. SL. SZ. TZ. UG. ZW). Eurasian patent (AM. AZ. BY. KG. KZ. MD. RU. TJ. TM). European patent (AT. BE. CH. CY. DE, DK. ES. FJ. FR. GB, GR, IE, IT. LU, MC, NL, PT. SE. TR). OAPI patent (BF, BJ. CF. CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD. TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4 17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JF, KE, KG, KF, KR, KZ, LC, LK, LR, LS, LT, LU, LI', MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, 17N, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FT, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 20 June 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE EXPRESSION SYSTEM

(57) Abstract: There are provided DNA constructs, including replicable cloning vectors and expression vectors, comprising a bactenophage promoter operably linked to an outron sequence. The expression vectors provided by the invention are useful in the expression of recombinant polypeptides in host cells or organisms and are particularly useful in expression of recombinant polypeptides in nematode worms such as C, elegans.

INTERNATIONAL SEARCH REPORT

Intra 'lonal Application No PC I /EP 01/05794

		107/21	01/03/34
A. CLASSI IPC 7	FICATION OF SUBJECT MATTER C12N15/63 C12N15/67 C12N15/ A01K67/033	85 C07K14/005 C12	2N9/12
According to	o international Patent Classification (IPC) or to both national classific	cation and IPC	
	SEARCHED		
Minimum do IPC 7	ocumentation searched (classification system followed by classification C12N C07K A01K	lion symbols)	
Documental	tion searched other than minimum documentation to the extent that	such documents are included in the fields	s searched
1	aia base consulted during the international search (name of data by	•	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category *	Chatton of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.
X	WIRTZ E ET AL: "Gene expression by bacteriophage T3 and T7 RNA p in transgenic trypanosomes" NUCLEIC ACIDS RESEARCH, vol. 22, no. 19, 1994, pages 388 XP002196041 figure 8	olymerases	1,9
A	CONRAD R ET AL: "Insertion of p intron into the 5' untranslated a Caenorhabditis elegans gene co- into a trans-spliced gene" MOL CELL BIOL, vol. 11, no. 4, April 1991 (1991- pages 1921-1926, XP001073410 figure 18	region of nverts it	1-18
		-/	
X Funt	er documents are listed in the continuation of box C.	Patent family members are list	led in annex.
* Special ca	tegories of cited documents:	*T* later document published after the i	international filing date
consid	nt defining the general state of the art which is not ered to be of particular relevance focument but published on or after the international	or priority date and not in conflict w cited to understand the principle or invention "X" document of particular relevance, the	ith the application but theory underlying the
"L" docume which	ale nt which may throw doubts on priority: claim(s) or is cled to establish the publication date of another	cannot be considered novel or can involve an inventive step when the "Y" document of particular relevance; the	not be considered to document is taken alone
	or other special reason (as specified) entreferring to an oral disclosure, use, exhibition or	cannot be considered to involve and document is combined with one or	inventive step when the
other n *P* docume		ments, such combination being obtain the art. *&* document member of the same pate.	vious to a person skilled
Date of the a	actual completion of the international search	Date of mailing of the international	search report
1!	5 April 2002	29/04/2002	
Name and m	nailing address of the ISA	Authorized officer	
1	European Paleni Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx 31 651 epo nl.		
	Fax: (+31-70) 340-3016	Lonnoy, O	

Form PCT/ISA/210 (second sheet) (July 1992)

1

INTERNATIONAL SEARCH REPORT

Intr Ional Application No PC+/EP 01/05794

		PC:/EP 01/05794
<u> </u>	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to ctalm No.
A	WO OO 01846 A (MORTIER KATHERINE ;DEVGEN NV (BE); BOGAERT THIERRY (BE); PLAETINCK) 13 January 2000 (2000-01-13) cited in the application pGN401	1-18
A	WO 99 37770 A (DEVGEN NV ;BOGAERT THIERRY ANDRE OLIVER E (BE); CRIEKINGE WIM MARI) 29 July 1999 (1999-07-29) figure 1E	1
A	KRAUSE M: "Transcription and Translation" METHODS CELL BIOL , vol. 48, 1995, pages 483-512, XP001073411	
A	WO 91 00905 A (US HEALTH) 24 January 1991 (1991-01-24)	
A	WO 00 09734 A (INTRONN HOLDINGS LLC) 24 February 2000 (2000-02-24)	
A	WO 97 22250 A (INTRONN LLC ;MITCHELL LLOYD G (US)) 26 June 1997 (1997-06-26) figure 2	
Ρ,Χ	WO 01 32896 A (ALEXANDROV KIRILL ;JENA BIOSCIENCE GMBH (DE); GRUN MATHIAS (US)) 10 May 2001 (2001-05-10) figure 3	1-5, 8-10,13
		:
	•	
		·

1

15 1

INTERNATIONAL SEARCH REPORT

information on patent family members

Intr Vional Application No PC I /EP 01/05794

		·····			01/05794
Patent document cited in search report		Publication date		Patent tamily member(s)	Publication date
WO 0001846	A	13-01-2000	AU	4907999 A	24-01-2000
			BR	9911802 A	22-01-2002
			CN	1323354 T	21-11-2001
			DE	1093526 T1	11-10-2001
			MO	0001846 A2	13-01-2000
			EP	1093526 A2	25-04-2001
			GB	2349885 A	15-11-2000
			GB	2362885 A	05-12-2001
			NO	20010019 A	05-03-2001
 WO 9937770	A	29-07-1999	AU	2240899 A	09-08-1999
			ΑU	4608499 A	30-12-1999
			BR	9911097 A	13-02-2001
			CA	2318935 A1	29-07-1999
			CN	1305525 T	25-07-2001
			MO	9964586 A2	16-12-1999
			EP	1049776 A1	
					08-11-2000
			EP	1084242 A2	21-03-2001
			HU	0101593 A2	28-08-2001
			HU	0102349 A2	28-10-2001
			PL	342082 A1	21-05-2001
			PL	345951 A1	14-01-2002
			WO	9937770 A1	29-07-1999
WO 9100905	Α	24-01-1991	US	5135855 A	04-08-1992
			ΑT	157701 T	15-09-1997
			AU	642657 B2	28-10-1993
			AU	6034490 A	06-02-1991
			CA	2063427 A1	08-01-1991
			DE	69031389 D1	09-10-1997
			DE	69031389 T2	19-03-1998
			EP	0484374 A1	13-05-1992
			ËS	2109924 T3	01-02-1998
			JP	2525289 B2	14-08-1996
			JP	5501048 T	04-03-1993
			WO US	9100905 A1 5126251 A	24-01-1991 30-06-1992
		24-02-2000		6083702 A	04-07-2000
no 0007/34	4	74 OF FOOD	US	6280978 B1	28-08-2001
			AU	5673599 A	06-03-2000
			EP	1105513 A2	13-06-2001
			WO	0009734 A2	24-02-2000
		26-06-1997	US	6013487 A	11-01-2000
MO 3/2220	А	20 00-133/	AU	1329997 A	14-07-1997
					- : : :
			WO	9722250 A1	26-06-1997
			US	6083702 A	04-07-2000
			US	6280978 B1	28-08-2001
			AU	730305 B2	01-03-2001
			CA	2240494 A1	26-06-1997
			EP	0883344 A1	16-12-1998
			JP	2000515362 T	21-11-2000
WO 0132896	Α	10-05-2001	AU	1997901 A	14-05-2001
			WO	0132896 A1	10-05-2001

Form PCT/ISA/210 (patent family annex) (July 1992)

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER: _

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.